Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

T cell

" in MCE Product Catalog:

By Targets:	Itk (7) NAMPT (1) Tim3 (1) TOPK (3) Acyltransferase (1) ADC Cytotoxin (3) ADC Linker (1) Adenosine Receptor (3) Akt (4) Aldehyde Dehydrogenase (ALDH) (1) AMPK (6) Amyloid-β (3) Antibiotic (8) Antifolate (1) Apoptosis (80) Arenavirus (3) Aryl Hydrocarbon Receptor (3) Aurora Kinase (1) Autophagy (21) Bacterial (11) Bcl-2 Family (3) Bcr-Abl (8) Biochemical Assay Reagents (4) BMX Kinase (1) Btk (4) c-Fms (1) c-Kit (1) c-Met/HGFR (6) c-Myc (1) Calcium Channel (4) Casein Kinase (5) Caspase (5) Cathepsin (4) CCR (5) CD19 (4) CD2 (2) CD20 (5) CD28 (6) CD3 (20) CD6 (1) CDK (8) CFTR (1) Checkpoint Kinase (Chk) (1) COX (5) CRAC Channel (3) CTLA-4 (5) CXCR (7) DGK (4) Dipeptidyl Peptidase (1) DNA Alkylator/Crosslinker (2) DNA Stain (9) DNA-PK (1) DNA/RNA Synthesis (6) DOCK (1) Drug Metabolite (7) Drug-Linker Conjugates for ADC (3) DYRK (2) E1/E2/E3 Enzyme (2) EBI2/GPR183 (1) EGFR (45) Endogenous Metabolite (13) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (4) Eukaryotic Initiation Factor (eIF) (3) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (1) Ferroptosis (2) Fluorescent Dye (15) Free Fatty Acid Receptor (1) Fungal (6) GABA Receptor (1) Galectin (1) GHSR (1) Glucocorticoid Receptor (1) GSK-3 (1) Guanylate Cyclase (2) Haspin Kinase (1) HBV (1) HDAC (4) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (4) Histone Methyltransferase (2) HIV (19) HIV Protease (3) HSP (5) IFNAR (6) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (5) Integrin (6) Interleukin Related (21) Isotope-Labeled Compounds (4) JAK (4) Keap1-Nrf2 (1) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (1) Liposome (1) Lipoxygenase (1) LPL Receptor (1) MALT1 (1) MAP4K (5) MEK (1) Microtubule/Tubulin (5) MMP (4) Molecular Glues (5) Monoamine Oxidase (1) Necroptosis (2) NF-κB (8) NO Synthase (2) NOD-like Receptor (NLR) (1) Notch (1) Nuclear Factor of activated T Cells (NFAT) (9) Nucleoside Antimetabolite/Analog (5) Orexin Receptor (OX Receptor) (2) P-glycoprotein (2) p38 MAPK (5) Parasite (11) PD-1/PD-L1 (35) PDGFR (2) PDI (1) Phosphatase (8) Phosphodiesterase (PDE) (2) Phosphoglycerate Dehydrogenase (PHGDH) (1) Phospholipase (1) PI3K (6) Pim (1) PKC (6) Potassium Channel (2) PPAR (3) Prostaglandin Receptor (2) PROTACs (6) Proteasome (1) Proton Pump (3) RAR/RXR (2) Ras (4) Reactive Oxygen Species (8) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) ROR (7) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) SARS-CoV (8) Ser/Thr Protease (3) SHP2 (5) Sirtuin (1) Smo (1) Src (5) STAT (5) STING (1) TGF-β Receptor (1) TNF Receptor (13) Toll-like Receptor (TLR) (4) Topoisomerase (5) TRP Channel (3) VEGFR (1) Wnt (2) YB-1 (1) β-catenin (4) γ-secretase (1)
By Research Areas:	Cancer (355) Cardiovascular Disease (13) Endocrinology (6) Infection (56) Inflammation/Immunology (242) Metabolic Disease (35) Neurological Disease (28)

By Targets:

Itk (7)

NAMPT (1)

Tim3 (1)

TOPK (3)

Acyltransferase (1)

ADC Cytotoxin (3)

ADC Linker (1)

Adenosine Receptor (3)

Akt (4)

Aldehyde Dehydrogenase (ALDH) (1)

AMPK (6)

Amyloid-β (3)

Antibiotic (8)

Antifolate (1)

Apoptosis (80)

Arenavirus (3)

Aryl Hydrocarbon Receptor (3)

Aurora Kinase (1)

Autophagy (21)

Bacterial (11)

Bcl-2 Family (3)

Bcr-Abl (8)

Biochemical Assay Reagents (4)

BMX Kinase (1)

Btk (4)

c-Fms (1)

c-Kit (1)

c-Met/HGFR (6)

c-Myc (1)

Calcium Channel (4)

Casein Kinase (5)

Caspase (5)

Cathepsin (4)

CCR (5)

CD19 (4)

CD2 (2)

CD20 (5)

CD28 (6)

CD3 (20)

CD6 (1)

CDK (8)

CFTR (1)

Checkpoint Kinase (Chk) (1)

COX (5)

CRAC Channel (3)

CTLA-4 (5)

CXCR (7)

DGK (4)

Dipeptidyl Peptidase (1)

DNA Alkylator/Crosslinker (2)

DNA Stain (9)

DNA-PK (1)

DNA/RNA Synthesis (6)

DOCK (1)

Drug Metabolite (7)

Drug-Linker Conjugates for ADC (3)

DYRK (2)

E1/E2/E3 Enzyme (2)

EBI2/GPR183 (1)

EGFR (45)

Endogenous Metabolite (13)

Epigenetic Reader Domain (1)

Estrogen Receptor/ERR (4)

Eukaryotic Initiation Factor (eIF) (3)

Farnesyl Transferase (1)

Fatty Acid Synthase (FASN) (1)

Ferroptosis (2)

Fluorescent Dye (15)

Free Fatty Acid Receptor (1)

Fungal (6)

GABA Receptor (1)

Galectin (1)

GHSR (1)

Glucocorticoid Receptor (1)

GSK-3 (1)

Guanylate Cyclase (2)

Haspin Kinase (1)

HBV (1)

HDAC (4)

Hedgehog (1)

HIF/HIF Prolyl-Hydroxylase (2)

Histone Demethylase (4)

Histone Methyltransferase (2)

HIV (19)

HIV Protease (3)

HSP (5)

IFNAR (6)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (2)

Influenza Virus (5)

Integrin (6)

Interleukin Related (21)

Isotope-Labeled Compounds (4)

JAK (4)

Keap1-Nrf2 (1)

Ligands for E3 Ligase (4)

Ligands for Target Protein for PROTAC (1)

LIM Kinase (LIMK) (1)

Liposome (1)

Lipoxygenase (1)

LPL Receptor (1)

MALT1 (1)

MAP4K (5)

MEK (1)

Microtubule/Tubulin (5)

MMP (4)

Molecular Glues (5)

Monoamine Oxidase (1)

Necroptosis (2)

NF-κB (8)

NO Synthase (2)

NOD-like Receptor (NLR) (1)

Notch (1)

Nuclear Factor of activated T Cells (NFAT) (9)

Nucleoside Antimetabolite/Analog (5)

Orexin Receptor (OX Receptor) (2)

P-glycoprotein (2)

p38 MAPK (5)

Parasite (11)

PD-1/PD-L1 (35)

PDGFR (2)

PDI (1)

Phosphatase (8)

Phosphodiesterase (PDE) (2)

Phosphoglycerate Dehydrogenase (PHGDH) (1)

Phospholipase (1)

PI3K (6)

Pim (1)

PKC (6)

Potassium Channel (2)

PPAR (3)

Prostaglandin Receptor (2)

PROTACs (6)

Proteasome (1)

Proton Pump (3)

RAR/RXR (2)

Ras (4)

Reactive Oxygen Species (8)

Ribosomal S6 Kinase (RSK) (1)

RIP kinase (1)

ROR (7)

ROS Kinase (1)

Salt-inducible Kinase (SIK) (1)

SARS-CoV (8)

Ser/Thr Protease (3)

SHP2 (5)

Sirtuin (1)

Smo (1)

Src (5)

STAT (5)

STING (1)

TGF-β Receptor (1)

TNF Receptor (13)

Toll-like Receptor (TLR) (4)

Topoisomerase (5)

TRP Channel (3)

VEGFR (1)

Wnt (2)

YB-1 (1)

β-catenin (4)

γ-secretase (1)

By Research Areas:

Cancer (355)

Cardiovascular Disease (13)

Endocrinology (6)

Infection (56)

Inflammation/Immunology (242)

Metabolic Disease (35)

Neurological Disease (28)

543

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

252

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 Tim3

Cat. No.	Product Name	Target	Research Areas

HY-P9947

Efalizumab	Integrin	Others
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.

HY-144088

ZYF0033 HPK1-IN-22	MAP4K	Cancer Inflammation/Immunology
ZYF0033 (HPK1-IN-22, compound ZYF0033) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 decreases the phosphorylation of SLP76 (serine 376). ZYF0033 promotes anticancer immune responses. ZYF0033 inhibits tumor growth and caused increases intratumoral infiltration of DCs, NK cells, and CD107a⁺CD8⁺ T cells but decreased infiltration of regulatory T cells, PD-1⁺CD8⁺ T cells, TIM-3⁺CD8⁺ T cells, and LAG3⁺CD8⁺ T cells in the 4T-1 syngeneic mouse model.

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

HY-131140

BD750	JAK STAT	Cancer Inflammation/Immunology
BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC₅₀ values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation.

HY-126037

(±)-ML 209	ROR	Inflammation/Immunology
(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC₅₀ of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC₅₀ of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4⁺ T cells into other lineages, including Th1 and regulatory T cells.

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research.

HY-P99302

Lulizumab Humanized Anti-CD28 Recombinant Antibody	CD28	Inflammation/Immunology
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling.

HY-P99024

Glofitamab RO7082859	CD20	Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.

HY-148174

JNJ-3790339	DGK	Cancer
JNJ-3790339, a Ritanserin (HY-10791) analog, is a potent and selective diacylglycerol kinase (DGKα) inhibitor with an IC₅₀ of 9.6 μM. JNJ-3790339 has induction of toxicity in malignant cells, and improves ability to upregulate T cell activation.

HY-148494

Tivumecirnon FLX475	CCR	Cancer
Tivumecirnon (FLX475) is a potent CCR4 antagonist that blocks regulatory T cells that interfere with effective antitumor immune responses and has antitumor activity.

HY-19344

Lifitegrast SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease.

HY-19344A

Lifitegrast sodium SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease.

HY-141549

BPK-21	Others	Inflammation/Immunology
BPK-21, an active acrylamide, suppresses T cell activation through blockade of ERCC3 function. BPK-21 specifically targets C342 in the helicase ERCC3.

HY-123531

JNJ 10329670	Cathepsin	Inflammation/Immunology
JNJ 10329670 is a potent and selective noncovalent cathepsin S inhibitor with a K_i value of 34 nM for human cathepsin S. JNJ 10329670 blocks invariant chain proteolysis in B cells and dendritic cells, as well as antigen-induced T cell proliferation.

HY-W019721

Cyclosporin D	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A. Cyclosporin A is a potent immunosuppressant agent, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc).

HY-119347

Cirsilineol	IFNAR STAT	Cancer Inflammation/Immunology
Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4⁺ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.

HY-B0078

Dacarbazine Imidazole Carboxamide	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Dacarbazine is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/ml, respectively. Dacarbazine can be used for the research of metastatic malignant melanoma.

HY-B0078B

Dacarbazine hydrochloride Imidazole Carboxamide hydrochloride	Antibiotic	Cancer
Dacarbazine hydrochloride is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine hydrochloride inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/mL, respectively. Dacarbazine hydrochloride can be used for the research of metastatic malignant melanoma.

HY-B0172A

Isoallolithocholic acid 3β-Hydroxy-5α-cholanic acid	Others	Inflammation/Immunology
Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation.

HY-13624A

Epirubicin hydrochloride 4'-Epidoxorubicin hydrochloride	DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic	Cancer
Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.

HY-13624

Epirubicin 4'-Epidoxorubicin	DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic	Cancer
Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.

HY-18555

TMPA	AMPK	Cancer Metabolic Disease Inflammation/Immunology
TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation.

HY-P99259

Cabiralizumab FPA 008; Anti-Human CSF1R Recombinant Antibody	c-Fms	Cancer Inflammation/Immunology
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research.

HY-P99814

Pavurutamab AMG-701	CD3	Cancer Inflammation/Immunology
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-*B cell* maturation antigens (BCMA**). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).

HY-149213

LSD1-IN-24	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC₅₀ = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research.

HY-143869

HPK1-IN-28	MAP4K	Cancer
HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1).

HY-143870

HPK1-IN-29	MAP4K	Cancer
HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38).

HY-12521

GSK-5498A	CRAC Channel	Inflammation/Immunology
GSK-5498A is a selective CARC channel inhibitor (IC₅₀: 1 μM). GSK-5498A inhibits mediators release from mast cells and pro-inflammatory cytokines release from T cells. GSK-5498A can be used in the research of inflammatory disorders.

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8⁺ T cells and reduces T cell exhaustion.

HY-P3554

Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl	HIV	Infection
Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl (compound (CPF(LL)) is an HIV-1 inhibitor. Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl interacts with gp120 to block gp120 binding to CD4 and preserve CD4-dependent T cell function.

HY-P99680

Keliximab SB-210396; IDEC CE9.1	Interleukin Related	Cancer
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a K_i value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research.

HY-142937

RORγt agonist 2	ROR	Inflammation/Immunology
RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17).

HY-142938

RORγt agonist 3	ROR	Inflammation/Immunology
RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23).

HY-P2561

Influenza Matrix Protein (61-72)	Influenza Virus	Infection Inflammation/Immunology
Influenza Matrix Protein (61-72) is a peptide fragment derived from matrix protein of influenza viruses, corresponds to amino acids 61-72. Influenza Matrix Protein (61-72) is a specific epitope which can induce CD4⁺ T-cell response.

HY-145256

GABAA receptor agent 4	GABA Receptor	Neurological Disease
GABAA receptor agent 4 (compound 1e) is a potent γ-GABAAR antagonist with an K_i of 0.18 µM. GABAA receptor agent 4 efficiently rescues inhibition of T cell proliferation. GABAA receptor agent 4 has the immunomodulatory potential.

HY-143423A

(S)-MALT1-IN-5	MALT1	Cancer Inflammation/Immunology
(S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1).

HY-109520

Glatiramer acetate	Others	Inflammation/Immunology
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.

HY-129055

Isoeleutherin	Fungal	Inflammation/Immunology
Isoeleutherin is a naphthopyran derivative isolated from E. americana Merr. Et Heyne with anti-fungal, anti-viral, and anti-tumor activities. Isoeleutherin plays an important role in selective modulation of T helper cell-mediated immune responses.

HY-101093

CA-170	PD-1/PD-L1	Inflammation/Immunology Cancer
CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes.

HY-120785

SR1555	ROR	Inflammation/Immunology
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC₅₀ value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases.

HY-P99752

Nemvaleukin alfa ALKS 4230; RDB-1450	Interleukin Related	Cancer Inflammation/Immunology
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer.

HY-12072

Lck Inhibitor	Src	Inflammation/Immunology
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC₅₀s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis.

HY-146727

JAK3-IN-11	JAK	Inflammation/Immunology
JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC₅₀ value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study autoimmune diseases.

HY-153220

NX-2127	Btk	Cancer
NX-2127 is an orally and potent BTK inhibitor, inducing degradation of the mutated BTK^C481S in cells. NX-2127 inhibits proliferation of BTK^C481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells.

HY-18522

AA26-9	Phospholipase	Metabolic Disease
AA26-9 is a potent and broad spectrum serine hydrolase inhibitor. AA26-9 targets included serine peptidases, lipases, amidases, esterases, and thioesterases. AA26-9 shows inhibitory activity against approximately 1/3 of the 40+ serine hydrolases detected in immortalized T cell lines .

HY-P2560

LCMV GP (61-80)	Arenavirus	Infection Inflammation/Immunology
LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4⁺ T-cell response.

HY-P99238

Rolinsatamab	Interleukin Related	Cancer Inflammation/Immunology
Rolinsatamab is a potent dual IL-4 and IL-13 inhibitor as a fully humanized bispecific monoclonal antibody. Rolinsatamab chimeric antigen receptor sequence T cell. Rolinsatamab can be used in research of immune disease.

HY-134771

YM-341619 AS1617612	STAT	Inflammation/Immunology
YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC₅₀ of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 (IC₅₀=0.28 nM) without affecting Th1 cell differentiation. YM-341619 is a promising compound for the the research of allergic diseases, such as allergic asthma.

HY-102011

BMS-1166	PD-1/PD-L1	Cancer Inflammation/Immunology
BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.

HY-139780

JNJ-61803534	ROR	Inflammation/Immunology
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC₅₀ of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions.

HY-150725

ODN 1585	IFNAR TNF Receptor	Cancer Infection Inflammation/Immunology
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant.

HY-113962

7α,25-Dihydroxycholesterol 7α,25-OHC	EBI2/GPR183 Endogenous Metabolite	Inflammation/Immunology
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC₅₀=140 pM; K_d=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.

HY-101092

QS-21 Stimulon	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
QS-21, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21 stimulates Th2 humoral and Th1 cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells. QS-21 can activate the NLRP3 inflammasome with subsequent release of caspase-1 dependent cytokines, IL-1β and IL-18.

HY-N3796

Echinulin Echinuline	NF-κB	Inflammation/Immunology
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to NF-κB activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent.

HY-110177

SP-100030	NF-κB	Inflammation/Immunology
SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC₅₀s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA).

HY-P99687

Latikafusp AMG 256	PD-1/PD-L1	Cancer
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.

HY-W107464

G6PDi-1	PDI	Metabolic Disease Inflammation/Immunology
G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC₅₀ of 0.07 μM. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells.

HY-P99152

Muromonab	CD3	Cancer Inflammation/Immunology
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.

HY-P4046

HBV Seq2 aa:179-186	HIV	Inflammation/Immunology
HBV Seq2 aa:179-186 serve as effective motifs for CTL response in H-2b system after in vitro restimulation of the primed T cells. HBV Seq2 aa:179-186 is a novel epitope identified on the surface antigen of hepatitis B virus.

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Cancer Inflammation/Immunology
PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model.

HY-B0078A

Dacarbazine citrate Imidazole Carboxamide citrate	Apoptosis Antibiotic	Cancer
Dacarbazine citrate is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research of apoptosis and various cancers such as metastatic malignant melanoma.

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs.

HY-11011

A-770041	Src	Inflammation/Immunology
A-770041 is a selective and orally active Src-family Lck inhibitor. A-770041 inhibits Lck with an IC₅₀ value of 147 nM with the presence of 1 mM ATP. A-770041 shows 300-fold selective to Lck over Fyn, the other Src family kinase involved in T-cell signaling. A-770041 can be used for the research of acute rejection.

HY-12279A

Umbralisib tosylate TGR-1202 tosylate; RP5264 tosylate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach.

HY-12279C

Umbralisib hydrochloride TGR-1202 hydrochloride; RP5264 hydrochloride	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach.

HY-121638

CU-3	Apoptosis DGK	Cancer Inflammation/Immunology
CU-3 is the racemate of (5Z,2E)-CU-3. (5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells.

HY-151464

SHP2/HDAC-IN-1	SHP2 Phosphatase HDAC	Cancer Inflammation/Immunology
SHP2/HDAC-IN-1 is a dual allosteric SHP2/HDAC inhibitor with IC₅₀ values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch.

HY-N10295

Flavipin	Aryl Hydrocarbon Receptor	Inflammation/Immunology
Flavipin is an aryl hydrocarbon receptor (Ahr) agonist that induces the expression of Ahr downstream genes in mouse CD4⁺ T cells and CD11b⁺ macrophages. Flavipin inhibits the stabilizing function of Arid5a on Il23a 3′UTR, a newly identified target mRNA. Flavipin exhibits the DPPH free radical scavenging ability with IC₅₀ value of 7.2 μM, and has potent α-glucosidase inhibition with IC₅₀ value of 33.8 μM.

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer.

HY-12279

Umbralisib TGR-1202; RP5264	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach.

HY-12279B

Umbralisib sulfate TGR-1202 sulfate; RP-5264 sulfate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach.

HY-145239

PD-1/PD-L1-IN-13	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC₅₀ value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8⁺ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model.

HY-15815

Bromosporine	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS.

HY-P9975

Theralizumab TGN1412	CD28	Inflammation/Immunology
Theralizumab (TGN1412) is a superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can be used for the research of rheumatoid arthritis.

HY-P99904

Siplizumab MEDI-507	CD2	Inflammation/Immunology
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells.

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner.

HY-146231

SS47	PROTACs MAP4K	Cancer Inflammation/Immunology
SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the?in?vivo?antitumor efficacy of BCMA CAR-T cell research. HPK1, an?immunosuppressive?regulatory kinase, is a promising target for cancer immunotherapies.

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

HY-P3736

Myelopeptide-2 MP-2	Interleukin Related	Cancer
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.

HY-N4053

Heraclenin	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Heraclenin, a natural furanocoumarin, significantly inhibits T cell receptor-mediated proliferation in human primary T cells in a concentration-dependent manner by targeting nuclear factor of activated T-cells (NFAT).

HY-P1698

Reltecimod AB-103	Bacterial CD28	Infection Inflammation/Immunology
Reltecimod (AB-103) is a *T-cell-specific surface glycoprotein CD28 (TP44)* antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines.

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research.

HY-110251A

DFHBI-2T	DNA Stain	Others
DFHBI-2T is a membrane-permeable RNA aptamers-activated fluorescence probe (ex/em=500 nm/523 nm). DFHBI-2T is used to image RNA in live cells. Storage: protect from light.

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research.

HY-142102

T988C
(+)-T988C
Others Cancer

T988C is a heptacyclic epidithiodioxopiperazine (ETP) natural product. T988C shows strong cytotoxicity to cultured P388 leukemia cells.

HY-136427

KRM-III	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC₅₀ of ~5 μM. Anti-inflammatory activity.

HY-136498

T-705RMP	Drug Metabolite	Infection
T-705RMP, a phosphorylated metabolite of T-705, exhibits a very weak inhibitory effect on the IMP dehydrogenase (IMPDH) activities of the host cells, with an IC₅₀ of 601 μM.

HY-110251

DFHBI-1T	DNA Stain	Others
DFHBI-1T is a membrane-permeable RNA aptamers-activated fluorescence probe (ex/em=472 nm/507 nm). DFHBI-1T binds to RNA aptamers (Spinach, Spinach2, iSpinach, and Broccoli) and causes specific fluorescence and lower background fluorescence. DFHBI-1T is used to image RNA in live cells. Storage: protect from light.

HY-110113

CTA056	Btk	Cancer
CTA056 is an ITK (IL-2-inducible T-cell kinase) inhibitor with an IC₅₀ of 0.1 μM. CTA056 selectively targets malignant T cells and modulates oncomirs. CTA056 induces apoptosis and is a potential therapeutic agent for the research of T-cell leukemia and lymphoma.

HY-145289

Antitumor agent-37	Apoptosis	Cancer
Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues.

HY-145288

Antitumor agent-36	Apoptosis	Cancer
Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues.

HY-125930A

T-2513 hydrochloride	Topoisomerase DNA/RNA Synthesis	Cancer
T-2513 hydrochloride is a selective topoisomerase I inhibitor. T-2513 hydrochloride binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death.

HY-125930

T-2513	Topoisomerase DNA/RNA Synthesis	Cancer
T-2513 is a selective topoisomerase I inhibitor. T-2513 binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death.

HY-117233

UU-T02	β-catenin Wnt	Cancer Metabolic Disease
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a K_i of 1.36 μM. UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells.

HY-125961

T3Inh-1	Others	Cancer
T3Inh-1 is a potent and selective inhibitor of *ppGalNAc-T3* (IC₅₀=7 µM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream).

HY-B0172AS

Isoallolithocholic acid-d2 3β-Hydroxy-5α-cholanic acid-d₂	Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Autophagy	Neurological Disease
Isoallolithocholic acid-d₂ is the deuterium labeled Isoallolithocholic acid (HY-B0172A). Isoallolithocholic acid is a T cell regulator and enhances regulatory T cells (Tregs) differentiation[1][2].

HY-N6626

Pyraclostrobin	Fungal Bacterial	Infection Metabolic Disease
Pyraclostrobin is a strobilurin fungicide that inhibits mitochondrial complex III of fungal and mammalian cells. Pyraclostrobin induces triglyceride accumulation and triglyceride accumulation in 3T3-L1 cells.

HY-124756

SBI-425	Phosphatase	Cardiovascular Disease
SBI-425 is an orally active and potent TNAP (tissue-nonspecific alkaline phosphatase) inhibitor (IC₅₀=16 nM). SBI-425 inhibits TNAP in the vasculature, improving cardiovascular parameters and survival.

HY-P99827

Cobolimab TSR-022; GSK4069889	Tim3	Cancer
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC₅₀ value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).

HY-123295

HDAC3-IN-T247	HDAC	Cancer Infection
HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC₅₀ of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells.

HY-12461

WS6
Others Inflammation/Immunology

WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability).

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells* to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.

HY-P99945

Revdofilimab ABBV-368	Orexin Receptor (OX Receptor)	Cancer Inflammation/Immunology
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells.

HY-13701

Nelarabine 506U78; GW 506U78; Nelzarabine	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Nelarabine (506U78) is a nucleoside analogue and can be used for the research of T cell acute lymphoblastic leukemia (T-ALL).

HY-120075

TJ191	Apoptosis	Cancer
TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research.

HY-151506

Phospholipid PL1	Liposome	Cancer
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity.

HY-113636

Kazinol A
Others Cancer

Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2.
HY-19352

T56-LIMKi
T5601640
LIM Kinase (LIMK) Cancer

T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC₅₀ of 35.2 μM.

HY-120356A

T-1101 tosylate TAI-95 tosylate	Apoptosis	Cancer
T-1101 tosylate (TAI-95 tosylate) is a Hec1/Nek2 (Highly expressed in cancer 1 / NIMA-related kinase 2) inhibitor with antitumor activity. T-1101 tosylate is inactive toward normal cells, kinases and hERG

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.

HY-P2455

LLO (91-99) Listeriolysin O (91-99)	Bacterial	Inflammation/Immunology
LLO (91-99) (Listeriolysin O (91-99)), an exotoxin, is a class I MHC-restricted T-cell epitopes of listeriolysin (LLO). LLO (91-99) is an essential antigen for induction of T-cell mediated immunity in vivo.

HY-153456

Hedgehog IN-2
Hedgehog Cancer

Hedgehog IN-2 (Compound 20) is an inhibitor of Hedgehog pathway with an IC₅₀ value less than 0.003 μM in C3H10T1/2 cells.

HY-149164

BTB09089	Others	Inflammation/Immunology Neurological Disease
BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65) specific agonist. BTB09089 increases TDAG8 expression and regulates the cytokine production of T cells and macrophages.

HY-144672

A2A receptor antagonist 2	Adenosine Receptor	Cancer Inflammation/Immunology
A2A receptor antagonist 2 (Compound 57) is a potent, highly selective adenosine A_2A receptor (A_2AR) antagonist with an IC₅₀ of 8.3 nM.

HY-P99457

Balstilimab
AGEN2034
PD-1/PD-L1 Inflammation/Immunology

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1.

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Cancer Neurological Disease
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.

HY-145498

HDMAPP triammonium	TNF Receptor	Inflammation/Immunology
HDMAPP triammonium is a potent phosphoantigen in the ammonium form and the pyrophosphate form of (E)-HDMAPP. HDMAPP is also a potent activator of γδ T cells and can induce T cell stimulation in vitro (EC₅₀=0.39 nM, TNF-α).

HY-N4010

Iriflophenone
Others Cancer

Iriflophenone, isolated from Aquilaria sinensis, stimulates MCF-7 and T-47D human breast cancer cells proliferation.

HY-79256

MMAF-OMe Monomethyl auristatin F methyl ester	ADC Cytotoxin	Cancer
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC₅₀s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.

HY-129492

GNF4877	DYRK GSK-3	Metabolic Disease
GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC₅₀s of 6 nM and 16 nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC₅₀ of 0.66 μM for mouse β (R7T1) cells).

HY-P99033

Mosunetuzumab BTCT-4465A	CD20	Cancer Inflammation/Immunology
Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).

HY-N11648

Ganoderic acid T1	Apoptosis Caspase	Cancer Inflammation/Immunology
Ganoderic acid T1 is a deacetylated derivative of Ganoderic acid T. Ganoderic acid T1 attenuates antioxidant defense system and induces apoptosis of cancer cells. Ganoderic acid T1 decreases mitochondrial membrane potential and activates caspase-9 and caspase-3, to trigger apoptosis. Ganoderic acid T1 also increases the generation of intracellular ROS to produce pro-oxidant activities and cytotoxicity.

HY-108813

Belatacept BMS 224818; LEA 29Y	Others	Inflammation/Immunology
Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.

HY-125881

ASP1126	LPL Receptor	Inflammation/Immunology
ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC₅₀ values of 7.12 nM, 517 nM for hS1P₁ and hS1P₃, respectively. ASP1126 decreases the number of peripheral lymphocytes, naive T cells, central memory T cells and effector memory T cells in the peripheral blood. ASP1126 has the potential to be applied in clinical transplantation with improved safety profile.

HY-115756

4-Maleimidosalicylic acid
Others Others

4-Maleimidosalicylic acid is a polar maleimide, and does not suppress IL-2 production in JURKAT T cells.
HY-N11038

Drynachromoside A
Others Others

Drynachromoside A is a chromone glycoside. Drynachromoside A has biochemical effects on the osteoblastic (MC3T3-E1 cells) proliferation activities.
HY-N6729

HT-2 Toxin
Others Metabolic Disease

HT-2 Toxin is an active, deacetylated metabolite of the T-2 toxin. HT-2 toxin inhibits protein synthesis and cell proliferation in plants.

HY-125443

Lucialdehyde A	Others	Cancer
Lucialdehydes A is a lanostante-type triterpene aldehydes, isolated from the fruiting bodies of Ganoderma lucidum. Lucialdehydes A shows cytotoxic effects on tumor cells, including Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines.

HY-142517

EGFR-IN-25
EGFR Cancer

EGFR-IN-25 is a potent EGFR inhibitor with IC₅₀s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively.

HY-147696

SMTIN-T140	HSP AMPK Reactive Oxygen Species	Cancer
SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC₅₀ of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells.

HY-P99253

Mogamulizumab KW-0761	CCR	Cancer Inflammation/Immunology
Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).

HY-N3037

3-O-Acetyl-α-boswellic acid
α-Boswellic acid acetate
Others Inflammation/Immunology

3-O-Acetyl-α-boswellic acid suppresses T cell function.

HY-130254

Src Inhibitor 3	Src	Cancer Inflammation/Immunology
Src Inhibitor 3 is a potent, orally active c-terminal Src kinase (CSK) with IC₅₀ values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. Src Inhibitor 3 shows the ability to increase T cell proliferation induced by T cell receptor signaling.

HY-P2251

T-peptide	HIV Microtubule/Tubulin	Cancer Infection Inflammation/Immunology
T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

HY-15405

Teriflunomide A77 1726	Drug Metabolite	Inflammation/Immunology
Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation.

HY-144340

Antitumor agent-43	DNA/RNA Synthesis Apoptosis	Cancer
Antitumor agent-43 (Compound 4B) is a potent antitumor agent, with an IC₅₀of 0.5 µM for (T-24 cell). Antitumor agent-43 (Compound 4B) induces cell cycle arrest at G2/M phase.

HY-136522

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice.

HY-136523

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells.

HY-134950

(E)-C-HDMAPP ammonium	TNF Receptor	Inflammation/Immunology
(E)-C-HDMAPP ammonium, is a potent phosphoantigen in ammonium form as well as a pyrophosphonate form of (E)-HDMAPP. (E)-C-HDMAPP is also an effective activator of γδ-T cells, induces T-cell stimulatory responses in vitro (EC₅₀=0.91 nM for TNF-α release).

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active humanized monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells.

HY-122649

UU-T01	β-catenin	Cancer
UU-T01 is a selective inhibitor for *β-Catenin/T-cell* factor 4 protein-protein interaction (β-catenin/Tcf PPI) with an K_i** value of 3.14 µM. UU-T01 is directly combined with β-catenin, and the K_D value is 0.531 µM.

HY-146087

Autophagy inducer 4	Autophagy	Cancer
Autophagy inducer 4 is a Magnolol-based Mannich base derivatives, which can be used as an anticancer agent. Autophagy inducer 4 suppresses cancer cells via inducing autophagy. Autophagy inducer 4 has 76-fold improvement in cytotoxicity against T47D cells compared with Magnolol. Autophagy inducer 4 also possesses suppressive effects on migration of T47D and Hela cancer cells.

HY-144073

HPK1-IN-21
MAP4K Cancer

HPK1-IN-21 is a potent inhibitor of HPK1 kinase inhibitor (Ki=0.8 nM). HPK1-IN-21 also has orally active.

HY-126539

UBE2T/FANCL-IN-1	E1/E2/E3 Enzyme	Cancer
UBE2T/FANCL-IN-1 is a potent inhibitor of UBE2T/FANCL-mediated FANCD2 monoubiquitylation that sensitizes cells to the DNA cross-linking agent, Carboplatin.

HY-P1404

R8-T198wt
Pim Cancer

R8-T198wt is a cell-permeable carboxyl-terminal p27^Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.

HY-137433

Befotertinib D-0316	EGFR	Cancer
Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).

HY-P99394

Talquetamab JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

HY-W008859

Tetrac Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Integrin Endogenous Metabolite	Cancer
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.

HY-P9901

Ipilimumab MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.

HY-112823

Almonertinib HS-10296	EGFR	Cancer
Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer.

HY-112823A

Almonertinib mesylate HS-10296 mesylate	EGFR	Cancer
Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer.

HY-112823B

Almonertinib hydrochloride HS-10296 hydrochloride	EGFR	Cancer
Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer.

HY-12972

Mavelertinib PF-06747775	EGFR	Cancer
Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC₅₀s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC).

HY-126193

JS-K	NO Synthase Apoptosis	Cancer
JS-K is a NO donor that reacts with glutathione to generate NO at physiological pH. JS-K inhibits proliferation, induces apoptosis, and disrupts the cell cycle of Jurkat T acute lymphoblastic leukemia cells.

HY-P99038

Odronextamab	CD20	Cancer Inflammation/Immunology
Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells.

HY-112296

T025	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research.

HY-106934

Peldesine BCX 34	Nucleoside Antimetabolite/Analog HIV	Cancer Infection Inflammation/Immunology
Peldesine (BCX 34) is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC₅₀s of 36 nM, 5 nM, and 32 nM for *human, rat, and mouse red blood cell* (RBC) PNP, respectively. Peldesine is also a T-cell proliferation inhibitor with an IC₅₀** of 800 nM. Peldesine has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research.

HY-106934A

Peldesine dihydrochloride BCX 34 dihydrochloride	Nucleoside Antimetabolite/Analog HIV	Cancer Infection Inflammation/Immunology
Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC₅₀s of 36 nM, 5 nM, and 32 nM for *human, rat, and mouse red blood cell* (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC₅₀** of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research.

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).

HY-125832

PBDB-T
Biochemical Assay Reagents Others

PBDB-T is a wide bandgap polymer donor in Perylene diimide (PDI)-based polymer solar cells (PSCs).

HY-112125A

KRN2 bromide	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
KRN2 (bromide) is a selective inhibitor of *nuclear factor of activated T cells* (NFAT5), with an IC₅₀** of 0.1 μM.

HY-141582

Ceramide 3 N-Stearoyl phytosphingosine	Biochemical Assay Reagents	Others
C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation.

HY-146136

EGFR-IN-56	EGFR Apoptosis	Cancer
EGFR-IN-56 (Compound 13a) is a potent EGFR inhibitor with IC₅₀ values of 541.7 nM and 132.1 nM against EGFR^T790M and EGFR^T790M/L858R, respectively. EGFR-IN-56 blocks cancer cells in G2/M phase and induce into late apoptosis.

HY-151120

Anticancer agent 79	Others	Cancer
Anticancer agent 79 (compound 3d) shows good anti-breast cancer activity. Anticancer agent 79 shows good cytotoxic activity in T47-D cells, with an IC₅₀ of 13.64 ± 0.26 μM.

HY-111446

EPAC 5376753
Ras Cancer Metabolic Disease Cardiovascular Disease

EPAC 5376753 is an allosterically inhibitor of Epac which inhibits Epac1 with an IC₅₀ of 4 µM in Swiss 3T3 cells.

HY-145879

Nrf2 activator-2	Keap1-Nrf2	Cancer
Nrf2 activator-2 (compound O15), a Osthole derivative, is a potent Nrf2 agonist with an EC₅₀ of 2.9 μM in 293 T cells. Nrf2 activator-2 effectively inhibits the interaction between Keap1 and Nrf2, thus showing the activation effect on Nrf2. Nrf2 activator-2 shows a marked decrease in the level of ubiquitinated Nrf2 in cells.

HY-P3410

Trichomide A	SHP2 Phosphatase	Inflammation/Immunology
Trichomide A is a potent activator of SHP2. Trichomide A is a natural cyclodepsipeptide. Trichomide A displays immunosuppressive activity against activated T lymphocyte–mediated immune responses in Con A-activated T cells. Trichomide A have the potential for the research of immune-related skin diseases.

HY-P1430

11R-VIVIT	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT can be used for the research of podocyte and diabetic nephropathy.

HY-114440

Belapectin GR-MD-02	Galectin Apoptosis	Cancer
Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity K_i of 2.8 μM.

HY-125664

Lucialdehyde B	Antibiotic	Cancer
Lucialdehyde B is a tetracyclic triterpene isolated from the substrates of Ganoderma lucidum with antiviral and cytotoxic activities. Lucialdehyde B has cytotoxic effects against Lewis lung cancer (LLC), T-47D, Sarcoma 180 and Meth-A tumor cell lines.

HY-N7087

Tulipalin A α-Methylene butyrolactone	Drug Metabolite
Tulipalin A (α-Methylene butyrolactone) is a glycoside. Tulipalin A is a causative allergen that induces Allergic contact dermatitides. Tulipalin A (α-Methylene butyrolactone) at low dose affects the functionality of immune cells, such as Jurkat T cells.

HY-N9737

(−)-Acutumine	Others	Neurological Disease
(−)-Acutumine is a tetracyclic chloroalkaloid that exhibits selective cytotoxicity to cultured human T cells and memory-enhancing properties in the Wistar rat model.

HY-P99679

Izuralimab
PD-1/PD-L1 Cancer Inflammation/Immunology

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.
HY-147311

NSC622608
PD-1/PD-L1 Inflammation/Immunology

NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC₅₀ value of 4.8 μM.

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies.

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of *B cell* lymphoma 6 (BCL6) with an IC₅₀** of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of *B cell* lymphoma 6 (BCL6), with an IC₅₀** of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.

HY-129767

CMLD012612	Eukaryotic Initiation Factor (eIF)	Cancer
CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC₅₀ value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity.

HY-P1430A

11R-VIVIT TFA	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy.

HY-125486

Reversin 121	P-glycoprotein	Cancer
Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers.

HY-P99280

Bimekizumab Anti-Human IL17A/IL-17F Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.

HY-P99408

Oxelumab R 4930; huMAb OX 40L; Ro 49-89991	Interleukin Related	Inflammation/Immunology
Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma.

HY-13563A

Batabulin sodium T138067 sodium	Microtubule/Tubulin Apoptosis	Cancer
Batabulin sodium (T138067 sodium) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin sodium affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death.

HY-13563

Batabulin T138067	Microtubule/Tubulin Apoptosis	Cancer
Batabulin (T138067) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death.

HY-N4171

Dihydrocucurbitacin B	Apoptosis	Inflammation/Immunology
Dihydrocucurbitacin B, a triterpene isolated from Cayaponia tayuya roots, inhibits nuclear factor of activated T cells (NFAT), induces cell cycle arrested in the G0 phase, and inhibits delayed type hypersensitivity.

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of *B cell* lymphoma 6 (BCL6), with an IC₅₀** of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.

HY-142680

EGFR-IN-23
EGFR Cancer

EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC₅₀ of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8).
HY-15440

Temsavir
BMS-626529
HIV Infection

Temsavir (BMS-626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4⁺ T cells.

HY-150543

Steroid sulfatase-IN-3	Others	Cancer
Steroid sulfatase-IN-3 (compound 1q) is a potent STS (Steroid sulfatase) inhibitor, with an IC₅₀ of 25.8 nM. Steroid sulfatase-IN-3 shows antiproliferative activity against T-47D estrogen-dependent breast cancer cells, with an IC₅₀ of 1.04 µM.

HY-110111

T2AA	DNA/RNA Synthesis	Cancer
T2AA is a monoubiquitinated proliferating cell nuclear antigen (PCNA) inhibitor that prevents DNA repair, increases double-strand break (DSB) formation and promotes necroptosis and cell cycle arrest in G1 phase.

HY-146071

Antitrypanosomal agent 5	Parasite	Infection
Antitrypanosomal agent 5 (Compound 25)is a selective anti-trypanosomal agent with IC₅₀s of 1 nM and 483.3 µM against T. brucei cell growth and HEK293 cells growth , respectively.

HY-148243

IGUANA-1 free base STL5-T-0057	Aldehyde Dehydrogenase (ALDH)	Cancer
IGUANA-1 free base (STL5-T-0057) is an selective ALDH1 B1 inhibitor with an IC₅₀ value of 30 nM. IGUANA-1 free base inhibits cell growth of SW480 cells in adherent and spheroid conditions with IC₅₀ values of 2.46 and 0.39 μM, respectively. IGUANA-1 free base can be used for the research of cancer.

HY-113618A

RO2959 hydrochloride	CRAC Channel Interleukin Related	Cardiovascular Disease
RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC₅₀ of 402 nM. RO2959 hydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC₅₀ of 25 nM. RO2959 hydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.

HY-129769

CMLD012073	Eukaryotic Initiation Factor (eIF)	Cancer
CMLD012073 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012073 inhibits the growth of NIH/3T3 cells with an IC₅₀ of 10 nM. CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A).

HY-104026B

L-Kynurenine sulfate	Endogenous Metabolite Aryl Hydrocarbon Receptor	Inflammation/Immunology
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype.

HY-N7915

Nepasaikosaponin K	Influenza Virus	Infection
Nepasaikosaponin K is an anti-influenza agent. Nepasaikosaponin K shows an EC₅₀ of 17.91 μM against influenza virus A/WSN/33 (H1N1) in 239T-Gluc cells.

HY-139920

Oritinib SH-1028	EGFR	Cancer
Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFR^WT, EGFR^L858R, EGFR^L861Q, EGFR^L858R/T790M, EGFR^d746-750 and EGFR^{d746-750/T790M} kinases, with IC₅₀s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively.

HY-113618B

RO2959 monohydrochloride	CRAC Channel Interleukin Related	Cardiovascular Disease
RO2959 monohydrochloride is a potent and selective CRAC channel inhibitor with an IC₅₀ of 402 nM. RO2959 monohydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC₅₀ of 25 nM. RO2959 monohydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.

HY-144120

αGalCer-RBD	SARS-CoV	Infection
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist. RBD: receptor-binding domain

HY-N7122

Thymopentin	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).

HY-N7122A

Thymopentin acetate	Endogenous Metabolite	Cancer Inflammation/Immunology
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).

HY-18667

LTV-1	Phosphatase	Inflammation/Immunology
LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC₅₀ of 508 nM. LTV-1 has the potential for autoimmunity treatment.

HY-100365

Remetinostat SHP-141	HDAC	Cancer
Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma.

HY-P1736

Influenza HA (126-138)	Influenza Virus	Infection
Influenza HA (126-138) is a influenza virus hemagglutinin (HA) peptide comprising amino acids 126-138, induces thymic and peripheral T-cell apoptosis.

HY-114388

QM385	Others	Inflammation/Immunology
QM385 is a potent sepiapterin reductase (SPR) inhibitor with an IC₅₀ of 1.49 nM, which blocks T-cell proliferation and autoimmunity at nanomolar potency and with good oral bioavailability.

HY-P3747

Hemagglutinin (48-68)	Influenza Virus	Infection
Hemagglutinin (48-68) is the 48-68 fragment of influenza virus hemagglutinin. Hemagglutinin (48-68) can induce proliferation of the peptide specific T-cell clones.

HY-128947

CL2 Linker	ADC Linker	Cancer
CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in agent substitution (~6), cell binding (K_d ~1.2 nM), cytotoxicity (IC₅₀ ~2.2 nM), and serum stability in vitro (t_1/2 ~20 hours).

HY-129152

Ganoderic acid T-N	Influenza Virus	Infection
Ganoderic acid T-N, a triterpenoid, is a H5N1 and H1N1 influenza neuraminidase (NA) inhibitor with IC₅₀s of 2.7 μM and 42 μM, respectively. Ganoderic acid T-Q shows cytotoxicity against MCF7 cells (CC₅₀=24.4 μM).

HY-10955

TTA-P1	Calcium Channel	Neurological Disease
TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy.

HY-N7038

Phytohemagglutinin PHA-M	Others	Inflammation/Immunology
Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, Phaseolus vulgaris, accumulates in the parenchyma cells of the cotyledons. Phytohemagglutinin is a T-cell activator. Stimulation of human mononuclear leukocytes by Phytohemagglutinin induces the expression of ChAT mRNA, and potentiated ACh synthesis.

HY-113042

Prostaglandin B2	Endogenous Metabolite	Endocrinology Cardiovascular Disease
Prostaglandin B2 is a prostaglandin. Prostaglandin B2 is the main substance in cord blood mesenchymal stem cells, to inhibit DC-T Cell proliferation. Prostaglandin B2 also induces cutaneous vasoconstriction of the canine hind paw.

HY-119339

SX-682	CXCR	Cancer Inflammation/Immunology Endocrinology
SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.

HY-128726

ITK inhibitor 2	Itk	Inflammation/Immunology
ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC₅₀ of 2 nM.

HY-135898

DGK-IN-1
DGK Cancer Inflammation/Immunology

DGK-IN-1 is a T cell activator extracted from patent WO2020006018A1, example 25. DGK-IN-1 can be used for tumor immunity.

HY-N6729S2

HT-2 Toxin-13C22	Isotope-Labeled Compounds	Metabolic Disease
HT-2 Toxin-¹³C₂₂ is ¹³C-labeled HT-2 Toxin (HY-N6729). HT-2 Toxin is an active, deacetylated metabolite of the T-2 toxin. HT-2 toxin inhibits protein synthesis and cell proliferation in plants.

HY-102052

DCEBIO	Potassium Channel	Inflammation/Immunology
DCEBIO, a derivative of 1-EBIO, is an extremely potent activator of Cl^- secretion in T84 colonic cells. DCEBIO stimulates Cl^- secretion via the activation of hIK1 K⁺ channels and the activation of an apical membrane Cl^- conductance.

HY-116609

C6 L-threo Ceramide	Interleukin Related	Inflammation/Immunology
C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. C6 L-threo Ceramide significantly inhibits IL-4 production in T cells. Anti-allergic agents.

HY-126675A

AS2863619	CDK STAT	Inflammation/Immunology
AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene.

HY-19617A

EGFR-IN-1 hydrochloride	EGFR	Cancer
EGFR-IN-1 hydrochloride is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 hydrochloride potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 hydrochloride displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity.

HY-101450

PF-6274484	EGFR	Cancer
PF-6274484 is a potent EGFR inhibitor with K_is of 0.14 nM and 0.18 nM for EGFR-L858R/T790M and WT EGFR, respectively. PF-6274484 inhibits EGFR-L858R/T790M autophosphorylation in H1975 tumor cells and EGFR WT in A549 tumor cells with IC₅₀s of 6.6 and 5.8 nM, respectively.

HY-P0323

GP(33-41)	Arenavirus	Infection
GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2D^b molecules at the RMA-S (Db Kb) cell surface with a SC₅₀ of 344 nM.

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.

HY-150203

GLPG3970	Salt-inducible Kinase (SIK)	Inflammation/Immunology
GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease.

HY-138542

RO0270608
Integrin Inflammation/Immunology

RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist. Antiinflammatory activity.

HY-P0323A

GP(33-41) TFA	Arenavirus	Infection
GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2D^b molecules at the RMA-S (Db Kb) cell surface with a SC₅₀ of 344 nM.

HY-P99908

Efineptakin alfa NT-17	Interleukin Related	Cancer
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4⁺ and CD8⁺ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research.

HY-124617A

AMXT-1501 tetrahydrochloride	Apoptosis	Cancer Inflammation/Immunology
AMXT-1501 tetrahydrochloride is an orally active polyamine transport inhibitor. AMXT1501 blocks tumor growth in immunocompetent mice but not in athymic nude mice lacking T cells. Combination of DFMO and AMXT‐1501 induces caspase‐3 mediated apoptosis in NB cell lines.

HY-P99420

Acazicolcept ALPN-101	CD28	Inflammation/Immunology
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual *inducible T cell* costimulator (ICOS)/CD28** antagonist. Acazicolcept has anti-inflammatory activities.

HY-147179

INX-SM-56	ADC Cytotoxin	Inflammation/Immunology
INX-SM-56 is a cytotoxin that can be used for the synthesis of anti-VISTA antibody agent conjugate. VISTA: V-region Immunoglobulin-containing Suppressor of T cell Activation.

HY-138102

SSAA09E3	SARS-CoV	Infection
SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC₅₀ of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC₅₀ of 0.15 μM.

HY-12316

20(S)-Hydroxycholesterol 20α-Hydroxycholesterol	Smo Endogenous Metabolite	Cancer
20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells.

HY-151207

Anticancer agent 81	Apoptosis ADC Cytotoxin	Cancer
Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab.

HY-124346

T-3364366	Others	Metabolic Disease
T-3364366 is a reversible, slow-binding, thienopyrimidinone delta-5 desaturase (D5D) inhibitor with IC₅₀s of 1.9 nM and 2.1 nM in HepG2 and RLN-10 cells, respectively. T-3364366 exhibits potent D5D (IC₅₀0=19 nM) inhibitory activity and excellent selectivity away from delta-6 desaturase (D6D, IC₅₀=6200 nM) and delta-9 desaturase (stearoyl-CoA desaturase, SCD,₅₀ >10000 nM) in the enzymatic activity assay.

HY-143445

EGFR-IN-48	EGFR	Cancer
EGFR-IN-48 is a potent and orally active EGFR inhibitor with IC₅₀s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR^d19/TM/CS, EGFR^LR/TM/CS, EGFR^WT, respectively. EGFR-IN-48 inhibits the proliferation of BaF3^{EGFR del19/T790M/C797S} and PC-9^{EGFR del19/T790M/C797S} cells with IC₅₀s of 1.526, 66.7 nM, respectively.

HY-P99521

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies.

HY-123159

AKI603	Aurora Kinase	Cancer
AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC₅₀ of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells.

HY-N6734

K-252b	PKC	Infection
K-252b, an indolocarbazole isolated from the actinomycete Nocardiopsis, is a PKC inhibitor. K-252b can be used to inhibit extracellular kinases of cells in culture because it can’t pass through cell membrane freely .

HY-32219

T863	Acyltransferase	Metabolic Disease
T863 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.

HY-14622

Necrostatin 2	RIP kinase	Cancer
Necrostatin 2 is a potent necroptosis inhibitor. EC₅₀ for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.

HY-142922

BCR-ABL-IN-4	Bcr-Abl	Cancer
BCR-ABL-IN-4 is a BCR-ABL inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC₅₀ values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11).

HY-126675

AS2863619 free base	CDK STAT	Inflammation/Immunology
AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene.

HY-19617B

EGFR-IN-1 TFA	EGFR	Cancer
EGFR-IN-1 TFA is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 TFA displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity.

HY-19617

EGFR-IN-1	EGFR	Cancer
EGFR-IN-1 (compound 24) is an orally active and irreversible L858R/T790M mutant selective EGFR inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 displays strong antiproliferative activity against the H1975 cells and the first line mutant HCC827 cells. Antitumor activity.

HY-P1052

Myelin Basic Protein(87-99)	Others	Inflammation/Immunology
Myelin Basic Protein(87-99) is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS).

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML).

HY-146472

EGFR-IN-52	EGFR Apoptosis	Cancer
EGFR-IN-52 (Compound 4) is a potent EGFR inhibitor with IC₅₀ values of 0.358, 86.02 and 432.67 µM against EGFR, EGFR L858R-TK and EGFR T790M-TK, respectively. EGFR-IN-52 shows cytotoxic activity against cancer cell lines and induces apoptosis.

HY-149920

Anticancer agent 98	Microtubule/Tubulin	Cancer
Anticancer agent 98 (compound 12k) is a microtubule/tubulin-polymerization inhibitor (K_d=16.9 μM). Anticancer agent 98 exerts antiproliferative potency against tumor cells, exhibits anti-angiogenesis effect in vitro. Anticancer agent 98 exhibits good human and mouse liver microsomes stability with both t_1/2>300 min.

HY-N7661

4β-Hydroxywithanolide E	PPAR	Metabolic Disease
4β-Hydroxywithanolide E, isolated from Physalis peruviana L., inhibits adipocyte differentiation of 3T3-L1 cells through modulation of mitotic clonal expansion. 4β-Hydroxywithanolide E is an adipogenesis inhibitor and inhibits PPARγ, C/EBPα, and the adipocyte-specific molecule aP2 mRNA expression.

HY-146471

EGFR-IN-51	EGFR Apoptosis	Cancer
EGFR-IN-51 (Compound 6) is a potent EGFR inhibitor with IC₅₀ values of 0.493, 102.60 and 461.63 µM against EGFR, EGFR L858R-TK and EGFR T790M-TK, respectively. EGFR-IN-51 shows cytotoxic activity against cancer cell lines and induces apoptosis.

HY-141864

ITK/TRKA-IN-1	Itk	Inflammation/Immunology
ITK/TRKA-IN-1 is a dual inhibitor of *IL-2-inducible T-cell* kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC₅₀** value of 1.0 nM and 96 % inhibition, respectively.

HY-P99040

Onvatilimab JNJ-61610588	PD-1/PD-L1	Cancer
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-*VISTA (V-domain Ig Suppressor of T-cell* Activation)** monoclonal antibody. Onvatilimab has an anti-tumor activity.

HY-102022

α-Galactosylceramide α-GalCer; KRN7000	Others	Cancer Inflammation/Immunology
α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor).

HY-126250

NPD-1335	Phosphodiesterase (PDE) Parasite	Infection Inflammation/Immunology
NPD1335 is a Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) inhibitor with submicromolar activities against T. brucei parasites. NPD1335 displays a greatly improved cytotoxicity profile. NPD1335 increases intracellular cAMP levels and results in the distortion of the cell cycle and cell death.

HY-P99776

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.

HY-145319

FPFT-2216	Phosphodiesterase (PDE) Casein Kinase Molecular Glues	Cancer Inflammation/Immunology
FPFT-2216, a “molecular glue” compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease.

HY-P99759

Nogapendekin alfa	Interleukin Related	Cancer Inflammation/Immunology
Nogapendekin alfa is a superagonist of IL-15. Nogapendekin alfa promotes the proliferation and viability of immune cells. Nogapendekin alfa combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form ALT-803, an IL-15 cytokine antibody fusion protein. ALT-803 reduces tumor burden by activation of NK cells and CD8⁺ T cells.

HY-108317

ABL127
Others Cancer

ABL127 is a selective and covalent inhibitor of protein methylesterase 1 (PME-1) with IC₅₀s of 6.4 nM and 4.2 nM in HEK293T and MDA-MB-231 cells, respectively.

HY-N6681

15-Acetoxyscirpenol	Caspase Bacterial Apoptosis Antibiotic	Infection
15-acetoxyscirpenol, one of acetoxyscirpenol moiety mycotoxins (ASMs), strongly induces apoptosis and inhibits Jurkat T cell growth in a dose-dependent manner by activating other caspases independent of caspase-3.

HY-P99717

Lulizumab pegol BMS-931699	CD28	Inflammation/Immunology
Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease.

HY-118047

CI 972 anhydrous	Nucleoside Antimetabolite/Analog	Inflammation/Immunology
CI 972 anhydrous is a potent, orally active, and competitive inhibitor of purine nucleoside phosphorylase (PNP) (K_i=0.83 μM) under development as a T cell-selective immunosuppressive agent.

HY-112125

KRN2	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
KRN2 is a selective inhibitor of *nuclear factor of activated T cells* (NFAT5), with an IC₅₀** of 100 nM. KRN2 has potential to treat NFAT5-mediated Chronic Arthritis.

HY-19816

Avitinib Abivertinib; AC0010	EGFR Btk	Cancer
Avitinib (AC0010) is an irreversible, mutant-selective EGFR inhibitor that effectively inhibits EGFR T790M resistance mutations in non-small cell lung cancer (NSCLC). Abivertinib is also a novel BTK inhibitor.

HY-19713

LJI308	Ribosomal S6 Kinase (RSK) YB-1	Cancer
LJI308 is a potent pan-ribosomal S6 kinase (RSK) inhibitor, with IC₅₀s of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. LJI308 inhibits the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation.

HY-146461

Anticancer agent 58	Apoptosis Caspase ROS Kinase	Cancer
Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC₅₀s of 0.6 μM and 0.7 μM, respectively. Anticancer agent 58 induces apoptosis by activating caspase 3/8/9 activity, and induces an increase of Ca²⁺ and ROS in cancer cells. Anticancer agent 58 significantly decreases mitochondrial membrane potential. Anticancer agent 58 can suppress tumor growth in T24 mouse xenograft model.

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors.

HY-B0190A

Nafamostat mesylate FUT-175	Ser/Thr Protease Apoptosis SARS-CoV	Cardiovascular Disease Cancer
Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat mesylate supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat mesylate blocks activation of SARS-CoV-2..

HY-B0190

Nafamostat	Ser/Thr Protease Apoptosis SARS-CoV	Cardiovascular Disease
Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2.

HY-128971

LHVS	Cathepsin Parasite	Infection Neurological Disease
LHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC₅₀ of 10 μM.

HY-B0190B

Nafamostat hydrochloride	Ser/Thr Protease Apoptosis SARS-CoV	Cardiovascular Disease
Nafamostat hydrochloride, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat hydrochloride supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat hydrochloride blocks activation of SARS-CoV-2..

HY-N7119

Cimicifugoside	Others	Inflammation/Immunology
Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function.

HY-18959

CWP232228	β-catenin Wnt	Cancer
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs).

HY-N4215

11(α)-Methoxysaikosaponin F	Others	Inflammation/Immunology
11(α)-Methoxysaikosaponin F is a triterpenoid saponin isolated from Bupleurum marginatum Wall.ex DC(ZYCH) which is a promising therapeutic for liver fibrosis. 11(α)-Methoxysaikosaponin F has an IC₅₀ of 387.7 nM with viability of hepatic stellate cells-T6 (HSCs-T6). Triterpenoid saponins have numerous targets, important network positions, and strong inhibitory activity.

HY-14174

MRK-560	γ-secretase	Cancer Neurological Disease
MRK-560 is an orally active, brain barrier-penetrating γ-Secretase inhibitor, can potently reduces Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 also decreases mutant NOTCH1 processing by selectively inhibiting PSEN1. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL).

HY-138072

EMI1	EGFR	Cancer
EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC).

HY-150610

EGFR-IN-69	EGFR	Cancer
EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC₅₀ values of 4.3, 6.6 and 25.6 nM against EGFR^{L858R/T790M/C797S}, EGFR^L858R/T790M, and EGFR^{19del/T790M/C797S}, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research.

HY-100891

CD80-IN-3
CD28 Inflammation/Immunology

CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC₅₀ of 630 nM and a K_d of 125 nM.

HY-151460

GCN2-IN-7	Others	Cancer
GCN2-IN-7 (compound 39) is an orally active and selective general control nonderepressible 2 (GCN2) inhibitor (IC₅₀=5 nM). GCN2-IN-7 shows anti-tumor activity in vivo.

HY-N10196

Cerebroside D	Endogenous Metabolite	Inflammation/Immunology
Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes.

HY-119217

AZ084	CCR	Inflammation/Immunology Endocrinology
AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a K_i of 0.9 nM. Has potential to treat asthma. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer.

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively.

HY-151435

CCR6 antagonist 1	CCR	Inflammation/Immunology
CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

HY-15888

PTC-209	Autophagy	Cancer
PTC-209 is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment.

HY-14171S

Bexarotene-d4 LGD1069 d₄	RAR/RXR Autophagy	Cancer
Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

HY-148803

Vabametkib	c-Met/HGFR	Cancer
Vabametkib is a potent inhibitor of hepatocyte growth factor receptor (HGFR). Vabametkib inhibits Hs746T cells proliferation and inhibits c-Met with an IC₅₀ value of 7 nM. Vabametkib can be used as an antineoplastic agent.

HY-109108

Valemetostat DS-3201	Histone Methyltransferase	Cancer
Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma.

HY-111149A

PS372424 hydrochloride	CXCR	Inflammation/Immunology
PS372424 hydrochloride, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 hydrochloride prevents human T-cell migration in a humanized model of arthritic inflammation.

HY-111149

PS372424	CXCR	Inflammation/Immunology
PS372424, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 prevents human T-cell migration in a humanized model of arthritic inflammation.

HY-15440A

Fostemsavir BMS-663068	HIV	Infection
Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4⁺ T cells.

HY-109108A

Valemetostat tosylate DS-3201 tosylate	Histone Methyltransferase	Cancer
Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma.

HY-101522

CHMFL-EGFR-202	EGFR BMX Kinase Btk MEK	Cancer
CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC₅₀s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ～10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines.

HY-142682

SCP1-IN-1	Others	Cancer Neurological Disease
SCP1-IN-1 (compound SH T-62) is a potent and selective covalent inhibitor against SCP1. SCP1-IN-1 promotes REST degradation and reduces transcriptional activity. A high level of REST protein drives the tumor growth in some glioblastoma cells. SCP1-IN-1 has the potential for the research of glioblastoma whose growth is driven by REST transcription activity.

HY-142683

SCP1-IN-2	Others	Cancer Neurological Disease
SCP1-IN-2 (Compound SH T-65) is a potent and selective covalent inhibitor against SCP1. SCP1-IN-2 promotes REST degradation and reduces transcriptional activity. A high level of REST protein drives the tumor growth in some glioblastoma cells. SCP1-IN-2 has the potential for the research of glioblastoma whose growth is driven by REST transcription activity.

HY-123418

PKUMDL-WQ-2201	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PKUMDL-WQ-2201 is a PHGDH non-NAD+-competing allosteric inhibitor (IC₅₀=35.7 μM). PKUMDL-WQ-2201 also inhibits PHGDH mutants with IC₅₀s of 69 μM (T59A) and >300 μM (T56AK57A), respectively. PKUMDL-WQ-2201 inhibits de novo serine synthesis in cancer cells, and reduces tumor growth.

HY-P99565

Tengonermin ARENEGYR; NGR-TNF; NGR-hTNF	TNF Receptor	Cancer
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment.

HY-N1506

Ganodermanontriol	Others	Cancer
Ganodermanontriol, a sterol isolated from Ganoderma lucidum, induces anti-inflammatory activity in tert-butyl hydroperoxide (t-BHP)-damaged hepatic cells through the expression of HO-1. Ganodermanontriol exhibits hepatoprotective activity.

HY-124416

ML604086	CCR	Inflammation/Immunology Endocrinology
ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca²⁺ concentrations.

HY-N1724

Concanamycin A Antibiotic X 4357B; Folimycin; X 4357B	Proton Pump Bacterial Antibiotic	Cancer Infection Inflammation/Immunology
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H⁺-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research^-.

HY-149916

A2AR-antagonist-1	Adenosine Receptor	Cancer
A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC₅₀=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t_1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2).

HY-18676

OSU-T315	Integrin Autophagy Apoptosis	Cancer
OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC₅₀ of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy.

HY-147708

T-Type calcium channel inhibitor 2	Calcium Channel	Cancer
T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC₅₀s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC₅₀s of 5.0, 6.4 µM, respectively.

HY-103275

Adaphostin NSC 680410	Bcr-Abl Apoptosis	Cancer
Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210^bcr/abl inhibitor (IC₅₀=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC₅₀ ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells.

HY-122716

PTGR2-IN-1	PPAR	Others
PTGR2-IN-1 is a potent PTGR2 inhibitor with an IC₅₀ of ~0.7 μM. PTGR2-IN-1 increases 15-keto-PGE2-dependent PPARγ transcriptional activity in PTGR2-transfected HEK293T cells.

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo.

HY-N0990

1,5,15-Trimethylmorindol	Others	Cancer
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay.

HY-147826

EGFR-IN-60	EGFR Apoptosis	Cancer
EGFR-IN-60 (Compound 7d) shows obvious inhibition of EGFR^WT, EGFR^T790M, EGFR^L858R and JAK3 with IC₅₀s of 83, 26, 53, and 69 nM, respectively. EGFR-IN-60 potently inhibits the growth of H1975 cells harboring EGFR^T790M mutation (IC₅₀=1.32 µM) over A431 cells overexpressing EGFR^WT (IC₅₀=4.96 µM). EGFR-IN-60 exhibits good oral absorption, potent and safe antitumor activity. EGFR-IN-60 induces cell death through apoptosis supported by increased Bax/Bcl-2 ratio.

HY-112870

Alflutinib Furmonertinib; AST2818	EGFR	Cancer
Alflutinib is a potent inhibitor of EGFR. Alflutinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).

HY-151981

EGFR-IN-74
EGFR Cancer

EGFR-IN-74 (Compound 21) is a potent EGFR inhibitor with an IC₅₀ of 138 nM against EGFR L858R/T790M. EGFR-IN-74 induces cancer cell apoptosis.

HY-N10846

Neotriptonoterpene	Others	Others
Neotriptonoterpene, a compound isolated from T. regelii, shows weak cytotoxic activity against A2780, HepG2 and MCF-7 cells with IC₅₀ values of 65.80, 35.45 and 64.80 µM respectively.

HY-141432

Cbl-b-IN-3	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-3 (Compound 23) is a casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC₅₀ of < 1 nM. Cbl-b is an E3 ubiquitin ligase that negatively regulates T-cell activation.

HY-143246

EGFR kinase inhibitor 1	EGFR Apoptosis	Cancer
EGFR kinase inhibitor 1 is a potent EGFR inhibitor with IC₅₀s of 37, 1.7, >300 nM for WT, l885R/T790M, L858R/T790M/C797S, respectively. EGFR kinase inhibitor 1 induces apoptosis and cell cycle arrest at G0/G1-phase. EGFR kinase inhibitor 1 inhibits the cell motility. EGFR kinase inhibitor 1 shows antiproliferative and anti-tumor activity.

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer Inflammation/Immunology
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity.

HY-15888A

PTC-209 hydrobromide	Autophagy	Cancer
PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC₅₀ of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment.

HY-115947

Anticancer agent 33	Others	Cancer
Anticancer agent 33 (compound 3), a Squamocin and Bullatacin derivative, is a potent anticancer agent. Anticancer agent 33 shows high potency to inhibit 4T1 breast cancer cell line (A549, HeLa, HepG2 and MCF-7 cells) growth with IC₅₀s of 1.9-5.4 µM.

HY-143337

EGFR-IN-47	Apoptosis EGFR	Cancer
EGFR-IN-47 is a potent and orally active EGFR^{L858R/T790M/C797S} inhibitor with an IC₅₀ of 0.01 µM. EGFR-IN-47 induces cell cycle attest and cell apoptosis. EGFR-IN-47 has the potential for the research of NSCLC.

HY-P99052

Tislelizumab	PD-1/PD-L1	Cancer Inflammation/Immunology
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.

HY-112126

KRN5	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
KRN5, a derivative of KRN2, is an oral active *Nuclear factor of activated T cells* 5 (NFAT5) suppressor, with an IC₅₀** of 750 nM. KRN5 has potential to treat NFAT5-mediated Chronic Arthritis.

HY-149055

ACT-777991	CXCR	Inflammation/Immunology
ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11.

HY-P99354

Bavunalimab Anti-Human CTLA4xLAG3	CTLA-4	Cancer Inflammation/Immunology
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer.

HY-146261

HI5	Microtubule/Tubulin Indoleamine 2,3-Dioxygenase (IDO) Apoptosis	Cancer
HI5 is a potent tublin and IDO inhibitor, with an IC₅₀ value of 70 nM in HeLa cells. HI5 inhibit IDO expression and decrease kynurenine production, leading to stimulating T cells activation and proliferation. HI5 can inhibit tubulin polymerization and cell migration, cause G2/M phase arrest, and induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells. HI5 can be used for researching anticancer.

HY-15440B

Fostemsavir Tris BMS-663068 Tris	HIV	Infection
Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl proagent of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4⁺ T cells.

HY-16984

GNE-4997	Itk	Inflammation/Immunology
GNE-4997 is a potent and selective *interleukin-2-inducible T-cell* kinase (ITK) inhibitor with a K_i** of 0.09 nM, and the correlation between the basicity of solubilizing elements in GNE-4997 and off-target antiproliferative effects reduces cytotoxicity.

HY-114495

Caerulomycin A Cerulomycin; Caerulomycin	Fungal Antibiotic	Infection Inflammation/Immunology
Caerulomycin A (Cerulomycin; Caerulomycin), an antifungal compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases.

HY-120210

XY018	ROR	Cancer Inflammation/Immunology
XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).

HY-B0689A

Indinavir sulfate MK-639; L735524	HIV HIV Protease SARS-CoV Apoptosis MMP	Infection Cancer
Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CL^pro inhibitor.

HY-144497

HE-S2	PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Cancer Infection
HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity.

HY-B0689

Indinavir MK-639 free base; L-735524 free base	HIV HIV Protease Apoptosis MMP SARS-CoV	Inflammation/Immunology Cancer
Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CL^pro inhibitor.

HY-B0689B

Indinavir sulfate ethanolate MK-639 ethanolate; L735524 ethanolate	Apoptosis MMP HIV HIV Protease SARS-CoV	Cancer Infection
Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CL^pro inhibitor.

HY-15627A

Hoechst 33342 analog trihydrochloride	Fluorescent Dye DNA Stain	Others
Hoechst 33342 analog trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-124623

DNDI-8219	Parasite	Infection
DNDI-8219 (compound 58) is a potent selective and orally active trypanocidal agent, possessing inhibitory activity against **Trypanosoma cruzi (T.?cruzi) with an IC₅₀** of 0.4 μM. DNDI-8219 has low cytotoxicity (L6 cells IC₅₀ > 100 μM). DNDI-8219 can effectively cure chronic T.?cruzi infection and markedly reduce parasite burdens in mouse model. DNDI-8219 has good solubility, metabolic stability and safety.

HY-15629

HOE 32020	DNA Stain	Others
HOE 32020 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15625

Hoechst 33258 analog 3	DNA Stain	Others
Hoechst 33258 analog 3 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15559

Hoechst 33342 bisBenzimide H 33342; HOE 33342	Autophagy	Others
Hoechst 33342 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-146398

AMPK activator 6	AMPK	Metabolic Disease
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome.

HY-15562

HOE 32021	Fluorescent Dye	Others
HOE 32021 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15561

HOE-S 785026 meta-Hoechst	Fluorescent Dye	Cancer
HOE-S 785026 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15559A

Hoechst 33342 trihydrochloride bisBenzimide H 33342 trihydrochloride; HOE 33342 trihydrochloride	Autophagy	Others
Hoechst 33342 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15619

Hoechst S 769121 Nuclear yellow	Fluorescent Dye	Others
Hoechst S 769121 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15560

Hoechst 34580 HOE 34580	Amyloid-β	Neurological Disease
Hoechst 34580 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15630A

Hoechst 33342 analog 2 trihydrochloride	Fluorescent Dye	Others
Hoechst 33342 analog 2 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-N0930B

Galegine hydrochloride	AMPK Bacterial	Infection Metabolic Disease
Galegine hydrochloride, a guanidine derivative, contributes to weight loss in mice. Guanidine hydrochloride is the compound derived from G. officinalis, which gave rise to the biguanides, metformin and phenformin. Galegine hydrochloride activates AMPK in 3T3-L1 adipocytes and L6 myotubes, as well as in the H4IIE rat hepatoma and HEK293 human kidney cell lines. Galegine hydrochloride has antibacterial activity, with minimum inhibitory concentration of 4 mg/L against Staphylococcus aureus strains.

HY-15630

Hoechst 33342 analog 2	Fluorescent Dye	Cancer
Hoechst 33342 analog 2 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15563

HOE 33187	Fluorescent Dye	Others
HOE 33187 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15631

Hoechst 33258 analog 6	Fluorescent Dye	Others
Hoechst 33258 analog 6 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15558A

Hoechst 33258 trihydrochloride bisBenzimide H 33258 trihydrochloride; H 33258 trihydrochloride	Fluorescent Dye	Cancer
Hoechst 33258 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15561B

HOE-S 785026 trihydrochloride meta-Hoechst trihydrochloride	Fluorescent Dye	Others
HOE-S 785026 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15560B

Hoechst 34580 tetrahydrochloride HOE 34580 tetrahydrochloride	Amyloid-β	Neurological Disease
Hoechst 34580 tetrahydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15626

ortho-iodoHoechst 33258	Fluorescent Dye	Others
ortho-iodoHoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15627

Hoechst 33342 analog	Fluorescent Dye	Others
Hoechst 33342 analog is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15623

Hoechst 33258 analog	DNA Stain	Others
Hoechst 33258 analog is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15622

meta-iodoHoechst 33258	DNA Stain	Cancer
meta-iodoHoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15628

Hoechst 33258 analog 5	DNA Stain	Others
Hoechst 33258 analog 5 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-147860

EGFR-IN-61	EGFR	Cancer
EGFR-IN-61 (compound 22a) is a potent EGFR kinase inhibitor, with IC₅₀ values of 42 nM (L858R/T790 M), 137 nM (L858R/T790 M/C797S), and 743 nM (WT), respectively. EGFR-IN-61 shows antiproliferative activity against A549 and H1975 cell lines, with IC₅₀ values of 2.14 and 1.82 μM, respectively.

HY-15624

Hoechst 33258 analog 2	DNA Stain	Cancer
Hoechst 33258 analog 2 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15632

para-iodoHoechst 33258	Fluorescent Dye	Others
para-iodoHoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15558

Hoechst 33258 bisBenzimide H 33258; H 33258	Fluorescent Dye	Cancer
Hoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-114374

RO5461111	Cathepsin	Inflammation/Immunology
RO5461111 a highly specific and orally active antagonist of Cathepsin S with IC₅₀s of 0.4 nM (human Cathepsin S) and 0.5 nM (murine Cathepsin S), respectively. RO5461111 can effectively inhibit the activation of antigen-specific T cells and B cells. RO5461111 can improve pulmonary inflammation and lupus nephritis.

HY-115543

β-catenin-IN-37	β-catenin	Cancer
β-catenin-IN-37 is a selective *β-Catenin/T-cell* factor protein-protein interaction** (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC₅₀ values of 20 μM and 31 μM, respectively.

HY-B2145

Ilaprazole sodium IY-81149 sodium	Proton Pump TOPK	Cancer Inflammation/Immunology
Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H⁺/K⁺-ATPase in a dose-dependent manner with an IC₅₀ of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.

HY-N7844

N6-Benzyladenosine Benzyladenosine	Apoptosis Adenosine Receptor	Cancer Inflammation/Immunology
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma^-.

HY-150089

SRI-37240	CFTR	Inflammation/Immunology
SRI-37240 is a potent premature termination codons (PTCs) inhibitor. SRI-37240 suppresses CFTR nonsense mutations. SRI-37240 alters cellular translation termination at PTCs in HEK293T cells. SRI-37240 can also restore CFTR function in primary bronchial epithelial cells when combination with G418.

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4 Interleukin Related	Inflammation/Immunology
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

HY-112870A

Alflutinib mesylate Furmonertinib mesylate; AST2818 mesylate	EGFR	Cancer
Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).

HY-153085

CD19 CAR circRNA	CD19	Cancer Inflammation/Immunology
CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-153084

CD19 CAR mRNA	CD19	Cancer Inflammation/Immunology
CD19 CAR mRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-P3444

CD31 PECAM-1	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation^-.

HY-136895

AZ12672857	Prostaglandin Receptor	Cancer
AZ12672857 is an orally active inhibitor of EphB4 (IC₅₀=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC₅₀=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC₅₀=9 nM).

HY-101664

Ilaprazole IY-81149	Proton Pump TOPK	Cancer Inflammation/Immunology
Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H⁺/K⁺-ATPase in a dose-dependent manner with an IC₅₀ of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.

HY-P99660

Imvotamab IGM-2323	CD20 CD3	Cancer Inflammation/Immunology
Imvotamab (IGM-2323) is a CD20xCD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab is currently being developed for the treatment of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).

HY-12680

PRN694	Itk	Inflammation/Immunology
PRN694 is an irreversible, highly selective and potent covalent *interleukin-2-inducible T-cell* kinase (ITK) and resting lymphocyte kinase (RLK) dual inhibitor with IC₅₀*s of 0.3 nM and 1.4 nM, respectively. PRN694 exhibits extended target residence time on ITK and RLK, enabling durable attenuation of effector cells* in vitro and in vivo.

HY-150566

BCR-ABL-IN-5	Bcr-Abl	Cancer
BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-Abl^WT and Bcr-Abl^T3151 with the IC₅₀ value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells.

HY-104026BS

L-Kynurenine-13C10 sulfate	Aryl Hydrocarbon Receptor Endogenous Metabolite	Inflammation/Immunology
L-Kynurenine-¹³C₁₀ (sulfate) is the ¹³C labeled L-Kynurenine sulfate[1]. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR)?agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype[2].

HY-129578

Asperphenamate	Autophagy Cathepsin	Cancer Infection Inflammation/Immunology
Asperphenamate, a fungal metabolite of Aspergillus flatiipes with anti-cancer effect, exhibits IC₅₀ values of 92.3 μM, 96.5 μM and 97.9 μM in T47D, MDA-MB-231 and HL-60 cells, respectively.

HY-10446

Pralatrexate	Antifolate Apoptosis	Cancer
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a K_i of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment.

HY-111310

ML351	Lipoxygenase	Metabolic Disease Neurological Disease
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2. ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D.

HY-135805

JBJ-04-125-02	EGFR	Cancer
JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC₅₀ of 0.26 nM for EGFR^L858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFR^{L858R/T790M/C797S} signaling. JBJ-04-125-02 has anti-tumor activities.

HY-N0457

Chicoric acid Cichoric acid; Dicaffeoyltartaric acid	Reactive Oxygen Species Apoptosis	Metabolic Disease Inflammation/Immunology
Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects.

HY-N0097A

9-β-D-Arabinofuranosylguanine AraG	Others	Cancer
9-β-D-Arabinofuranosylguanine is a Guanosine (HY-N0097) analog and shows high affinity for deoxyguanosine kinase (dGK) with a K_m of 8.0 μM. 9-β-D-Arabinofuranosylguanine can be used for the research of T-cell lymphoblastic disease.

HY-139464

Q134R	Nuclear Factor of activated T Cells (NFAT)	Neurological Disease
Q134R, a neuroprotective hydroxyquinoline derivative that suppresses *nuclear factor of activated T cell* (NFAT)** signaling. Q134R can across blood-brain barrier. Q134R has the potential for Alzheimer's disease (AD) and aging-related disorders research.

HY-N7819

Pristane Norphytane	Others	Inflammation/Immunology
Pristane (Norphytane) is a naturally occurring hydrocarbon oil found in small quantities in many plants, in various marine organisms, and as the most active component of mineral oil. Pristane is a non-antigenic adjuvant, and induces MHC class II-restricted, arthritogenic T cells in the rat.

HY-P1566

MPG, HIV related	HIV	Infection
MPG, HIV related is 27-aa peptide, derived from both the nuclear localisation sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41 and is a potent delivery agent for the generalised delivery of nucleic acids and of oligonucleotides into cultured cells.

HY-N6857

Armepavine	NF-κB	Inflammation/Immunology
Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades.

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.

HY-108391

C8-Ceramide N-Octanoyl-D-erythro-sphingosine	Apoptosis PKC Autophagy	Cancer Inflammation/Immunology
C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro.

HY-P3444A

CD31 TFA PECAM-1 TFA	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation^-.

HY-N3523

3-O-Beta-D-Glucopyranosylplatycodigenin	Others	Cancer
3-O-Beta-D-Glucopyranosylplatycodigenin is an oleanane-type triterpenoid isolated from roots of Platycodon grandiflorum. 3-O-Beta-D-Glucopyranosylplatycodigenin exhibits anti-proliferative activities against HSC-T6 cell line with an IC₅₀ of 13.36 μM.

HY-151096

ACT-660602	CXCR	Inflammation/Immunology
ACT-660602 is an orally active antagonist of chemokine receptor (CXCR3) with an IC₅₀ value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. ACT-660602 can be used for autoimmune diseases research.

HY-13232

ITK antagonist	Itk	Inflammation/Immunology
ITK antagonist (compound 10 n) is a potent, orally active and selective ITK (Interleukin-2 inducible T-cell kinase) antagonist (IC₅₀=1 and 20 nM in different assays). ITK antagonist inhibits insulin receptor kinase (IRK) with an IC₅₀ of 160 nM.

HY-B0199

Mycophenolate Mofetil RS 61443; TM-MMF	Drug Metabolite Apoptosis Endogenous Metabolite Bacterial	Cancer
Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation.

HY-108583

Psora-4 5-(4-Phenylbutoxy)psoralen	Potassium Channel	Inflammation/Immunology
Psora-4 is a potent and selective inhibitor of K_v1.3 (voltage-gated potassium channels) with an EC₅₀ of 3 nM. Psora-4 has immunosuppressive activity and inhibits proliferation of human and rat myelin-specific effector memory T cells in vitro.

HY-147862

EGFR-IN-62	EGFR Apoptosis	Cancer
EGFR-IN-62 (compound 9h) is a potent and reversible EGFR kinase inhibitor, with IC₅₀ values of 10 nM (L858R/T790 M), 29 nM (WT), and 242 nM (L858R/T790 M/C797S), respectively. EGFR-IN-62 shows antiproliferative activity against A549 and H1975 cell lines, with IC₅₀ values of 2.53 and 1.56 μM, respectively. EGFR-IN-62 induces dose-dependent apoptosis process, G1/G0-phase arrestation, and the inhibition of motility on A549 and/or H1975 cell lines.

HY-150741

ODN 2216	Toll-like Receptor (TLR) IFNAR Interleukin Related	Cancer Infection Inflammation/Immunology
ODN 2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4⁺ T cells.

HY-144731

gp120-IN-2	HIV	Inflammation/Immunology
gp120-IN-2 (compound 4i) is a potent HIV-1 gp120 inhibitor with an IC₅₀ of 7.5 µM and CC₅₀ of 112.93 µM. gp120-IN-2 shows anti-HIV-1 activity. gp120-IN-2 shows cytotoxicity in a dose dependent manner in SUP-T1 cells.

HY-112615

NAMPT inhibitor-linker 1	Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC₅₀s of <3 pM and 9 pM, respectively.

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Cancer Inflammation/Immunology
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.

HY-19779

JTT 551	Phosphatase	Metabolic Disease
JTT 551 is selective a protein tyrosine phosphatase 1B (PTP1B) inhibitor, with K_is of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively; JTT 551 can be used in the research of type 2 diabetes mellitus.

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-108741

Plecanatide	Guanylate Cyclase	Inflammation/Immunology
Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis.

HY-144395

HDAC6-IN-4	HDAC Apoptosis	Cancer Inflammation/Immunology
HDAC6-IN-4 (C10) is a potent, orally active and highly selective HDAC6 inhibitor with an IC₅₀ value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity.

HY-N0704

Agrimol B	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Cancer Infection Metabolic Disease
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Cancer Inflammation/Immunology
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20⁺ non-Hodgkin lymphomas (NHL).

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-148029

Dazostinag disodium TAK-676	STING	Cancer
Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity.

HY-A0003A

Lenalidomide hydrochloride CC-5013 hydrochloride	Ligands for E3 Ligase Molecular Glues	Cancer Inflammation/Immunology
Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-A0003B

Lenalidomide hemihydrate CC-5013 hemihydrate	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-144730

gp120-IN-1	HIV	Inflammation/Immunology
gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an IC₅₀ of 2.2 µM and CC₅₀ of 100.90 µM. gp120-IN-1 shows anti-HIV-1 activity. gp120-IN-1 shows cytotoxicity in a dose dependent manner in SUP-T1 cells. gp120-IN-1 shows inhibition of gp120-mediated virus enter into cells.

HY-A0003

Lenalidomide CC-5013	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer Inflammation/Immunology
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

HY-P1854

β-Amyloid (1-9)	Amyloid-β	Neurological Disease
β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .

HY-128600

ERD-308	PROTACs Estrogen Receptor/ERR	Cancer
ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC₅₀ (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively).

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma.

HY-W009245

Bz-RS-iSer(3-Ph)-OMe	HIV	Infection
Bz-RS-iSer(3-Ph)-OMe (compound 2), a Taxol derivative, inhibits HSV replication cycle at low cytotoxicity, blocks mitotic divisions of Vero cells, influences M-MSV induced tumor size and affects immune response by inhibiting PHA-induced T lymphocyte proliferation.

HY-138751

limertinib ASK120067	EGFR	Cancer
limertinib (ASK120067) is a potent and orally active inhibitor of EGFR^T790M (IC₅₀:0.3 nM) with selectivity over EGFR^WT (IC₅₀:6.0 nM). limertinib is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC).

HY-12467

OTS964 hydrochloride	TOPK CDK Apoptosis	Cancer
OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC₅₀ of 28 nM. OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a K_d of 40 nM.

HY-P99378

Neihulizumab ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)	Apoptosis	Inflammation/Immunology
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research.

HY-W015445

SD-169	p38 MAPK	Metabolic Disease
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC₅₀ of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC₅₀ of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation.

HY-108829

Abatacept CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

HY-101775A

9-Hydroxyellipticine hydrochloride	Topoisomerase	Cancer Cardiovascular Disease
9-Hydroxyellipticine hydrochloride is a inhibitor of Topo II and RyR. 9-Hydroxyellipticine hydrochloride exhibits antitumor, antioxidant and catecholamine-releasing activities. 9-Hydroxyellipticine hydrochloride exhibits IC₅₀ values of 1.6 μM and 1.2μM in Hela S-3 and 293T cells, respectively.

HY-119944

JND3229	EGFR	Cancer
JND3229 is a reversible EGFR^C797S inhibitor with IC₅₀ values of 5.8, 6.8 and 30.5 nM for EGFR^{L858R/T790M/C797S}, EGFR^WT and EGFR^L858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma.

HY-131911

PROTAC IDO1 Degrader-1	PROTACs Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology
PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to Cereblon E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC₅₀=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells.

HY-107390

AX-024	TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology
AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.

HY-146561

S-HP210	Glucocorticoid Receptor NF-κB	Inflammation/Immunology
S-HP210 is a potent and selective glucocorticoid receptor (GR) with an IC₅₀ value of 1.92 μM for NF-κB transrepression (TR). S-HP210 represses the LPS-induced transcription of a variety of proinflammatory genes such as IL-1β, IL-6 and COX-2. S-HP210 is nontoxic at effective doses against mouse fibroblasts 3T3 cells.

HY-107390A

AX-024 hydrochloride	TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology
AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.

HY-153233

CD19 car mRNA-LNP	CD19	Cancer Inflammation/Immunology
CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-153234

CD19 car circRNA-LNP	CD19	Cancer Inflammation/Immunology
CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-119312

C8 Dihydroceramide	PKC	Cancer
C8 Dihydroceramide is a negative control of C8 Ceramide. C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro.

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619. NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH).

HY-114268

BRD-K98645985	HIV	Infection
BRD-K98645985 is a BAF (mammalian SWI/SNF) transcriptional repression inhibitor with an EC₅₀ of ~2.37 µM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, without T cell activation or toxicity.

HY-N0041

Ginsenoside Rb3 Gypenoside IV	NF-κB COX NO Synthase	Cancer Inflammation/Immunology
Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.

HY-144044

EGFR-IN-30	EGFR	Cancer
EGFR-IN-30 is a potent EGFR inhibitor with IC₅₀s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research.

HY-104037

Cintirorgon LYC-55716	ROR	Cancer
Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival.

HY-117433

4-Hydroperoxy cyclophosphamide	DNA Alkylator/Crosslinker Apoptosis Reactive Oxygen Species Drug Metabolite	Inflammation/Immunology
4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders.

HY-P99836

Cudarolimab IBI101	Orexin Receptor (OX Receptor)	Cancer Inflammation/Immunology
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.

HY-146672

ITK inhibitor 6	Itk	Cancer
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC₅₀s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities.

HY-114911

Feprazone DA2370; Prenazone; Zepelin	COX Reactive Oxygen Species MMP	Inflammation/Immunology
Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX)-2. Feprazone ameliorates free fatty acid (FFA)-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity.

HY-124750

NecroX-7	TNF Receptor Interleukin Related Toll-like Receptor (TLR) Reactive Oxygen Species	Inflammation/Immunology Cardiovascular Disease
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.

HY-13757A

Tamoxifen ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 µM and 1.8 µM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse.

HY-110350

CHR-6494 TFA	Haspin Kinase	Cancer
CHR-6494 TFA is a potent inhibitor of haspin, with an IC₅₀ of 2 nM. CHR-6494 TFA inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer.

HY-132304

CC-90005	PKC	Inflammation/Immunology
CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC₅₀ of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC₅₀=4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2 expression.

HY-50101A

Mavorixafor trihydrochloride AMD-070 trihydrochloride	CXCR HIV	Infection Endocrinology Cancer
Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.

HY-108741A

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis.

HY-P2724

Purine nucleoside phosphorylase PNP	Endogenous Metabolite	Metabolic Disease
Purine nucleoside phosphorylase is a key enzyme in purine metabolism, which is involved in the purine rescue pathway. The deficiency of Purine nucleoside phosphorylase resulted in impaired T cell function. In the presence of inorganic orthophosphate as the second substrate, Purine nucleoside phosphorylase catalyzes the breaking of the glycosidic bond between ribose and deoxyribonucleoside to generate purine base and ribose (deoxyribose) -1-phosphate.

HY-153090

Transketolase-IN-4	Bacterial	Cancer Infection
Transketolase-IN-4 is a potent transketolase inhibitor (IC₅₀=3.9 μM). Transketolase-IN-4 inhibits tumor cell proliferation of SW620, LS174T, and MIA PaCa-2. Transketolase-IN-4 is a possible Mycobacterium tuberculosis DXS inhibitor, with an IC50 value of 114.1 μM.

HY-139920A

Oritinib mesylate SH-1028 mesylate	EGFR	Cancer
Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of EGFR with an IC₅₀ of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations. Oritinib (SH-1028) mesylate significantly inhibits proliferation of tumor cells with EGFR sensitive and resistant mutation.

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.

HY-N6939

Pseudolaric Acid B	HBV Fungal Apoptosis Autophagy Ferroptosis	Cancer Infection Inflammation/Immunology
Pseudolaric Acid B is a diterpene isolated from the root of Pseudolarix kaempferi (pinaceae), has anti-cancer, antifungal, and antifertile activities, and shows immunosuppressive activity on T lymphocytes. Pseudolaric Acid B inhibits hepatitis B virus (HBV) secretion through apoptosis and cell cycle arrest. Pseudolaric Acid B induces autophagy.

HY-50101

Mavorixafor AMD-070	CXCR HIV	Infection Endocrinology Cancer
Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.

HY-N7819S

Pristane-d40	Isotope-Labeled Compounds	Inflammation/Immunology
Pristane-d₄₀ is the deuterium labeled Pristane[1]. Pristane (Norphytane) is a naturally occurring hydrocarbon oil found in small quantities in many plants, in various marine organisms, and as the most active component of mineral oil[2]. Pristane is a non-antigenic adjuvant, and induces MHC class II-restricted, arthritogenic T cells in the rat[3].

HY-146210

EGFR-IN-50	EGFR	Cancer
EGFR-IN-50 (Compound 9h) is a potent EGFR inhibitor against L858R resistance mutation (TEL-EGFR-L858R-BaF3: GI₅₀=8 nM, TEL-EGFR-T790M-L858R-BaF3: GI₅₀=6.03 μM). EGFR-IN-50 shows anti-proliferative activity to cancer cells.

HY-149917

ITK degrader 1	Itk	Cancer
ITK degrader 1 is a highly selective degrader of *interleukin-2-inducible T-cell* kinase (ITK; DC₅₀*=3.6 nM in vivo* in mice). ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC₅₀=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo. ITK degrader 1 also shows good plasma exposure levels.

HY-B1021

Vincamine	Free Fatty Acid Receptor	Metabolic Disease Cardiovascular Disease
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation. Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research.

HY-18696

AMG-337	c-Met/HGFR Caspase Apoptosis	Cancer
AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC₅₀ values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis.

HY-A0003S

Lenalidomide-d5 CC-5013-d₅	Ligands for E3 Ligase Molecular Glues Apoptosis	Cancer Inflammation/Immunology
Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-121638A

(5Z,2E)-CU-3	Apoptosis DGK	Cancer
(5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells.

HY-129550

BI-4020	EGFR	Cancer
BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC₅₀=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC₅₀=1 nM). BI-4020 also shows activity against EGFR wt (IC₅₀=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties.

HY-149079

Antiparasitic agent-15	Parasite Necroptosis	Infection
Antiparasitic agent-15, a pyridine-thiazolidinone, has anti-Trypanosoma cruzi and leishmanicidal activities. Antiparasitic agent-15 has IC₅₀s of 0.9 μM and 0.64 μM against trypomastigote and amastigote forms of T. cruzi. Antiparasitic agent-15 has IC₅₀s of 42.2 μM and 9.58 μM against trypomastigote and amastigote forms of L. amazonensis. Antiparasitic agent-15 induces parasite cell death through necrosis induction. Antiparasitic agent-15 induces morphological changes such as shortening, retraction and curvature of the parasite body and leakage of internal content with T. cruzi trypomastigotes.

HY-149080

Antiparasitic agent-16	Parasite Necroptosis	Infection
Antiparasitic agent-16, a pyridine-thiazolidinone, has anti-Trypanosoma cruzi and leishmanicidal activities. Antiparasitic agent-16 has IC₅₀s of 1.0 μM and 0.6 μM against trypomastigote and amastigote forms of T. cruzi. Antiparasitic agent-16 has IC₅₀s of 150.2 μM and 16.75 μM against trypomastigote and amastigote forms of L. amazonensis. Antiparasitic agent-16 induces parasite cell death through necrosis induction. Antiparasitic agent-16 induces morphological changes such as shortening, retraction and curvature of the parasite body and leakage of internal content with T. cruzi trypomastigotes.

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-101985

BV02	Bcr-Abl	Cancer
BV02 is a potent 4-3-3 PPI (14-3-3 protein–protein interaction) inhibitor. BV02 shows cytotoxicity for hematopoietic cells expressing the IM (imatinib mesylate)-sensitive wild type Bcr-Abl and the IM-resistant T315I mutation. BV02 has the potential for the research of chronic myeloid leukemia.

HY-17002

Suplatast (Tosilate) IPD 1151T	Interleukin Related	Inflammation/Immunology
Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity.

HY-N10648

PTP1B-IN-20	Phosphatase	Metabolic Disease
PTP1B-IN-20 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC₅₀=1.05 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC₅₀=78.0 μM), which is a key target for type 2 diabetes inhibition.

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function.

HY-B0199S

Mycophenolate Mofetil-d4	Isotope-Labeled Compounds Drug Metabolite Apoptosis Endogenous Metabolite	Cancer
Mycophenolate Mofetil-d₄ is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].

HY-N10649

PTP1B-IN-21	Phosphatase	Metabolic Disease
PTP1B-IN-21 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC₅₀=1.56 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC₅₀>100 μM), which is a key target for type 2 diabetes inhibition.

HY-147858

PROTAC EGFR degrader 7	PROTACs EGFR Apoptosis	Cancer
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR^L858R/T790M degrader, with a DC₅₀ of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC₅₀ of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research.

HY-10261D

Afatinib oxalate BIBW 2992 oxalate	EGFR Autophagy Apoptosis c-Met/HGFR Akt	Cancer
Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.

HY-10261A

Afatinib dimaleate BIBW 2992MA2	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.

HY-10261

Afatinib BIBW 2992	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active TBK1 and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to PD-1 and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity.

HY-13757AS1

Tamoxifen-d3 ICI 47699-d₃; (Z)-Tamoxifen-d₃; trans-Tamoxifen-d₃	Estrogen Receptor/ERR Apoptosis Autophagy HSP	Cancer
Tamoxifen-d₃ is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].

HY-13757

Tamoxifen Citrate ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate	Estrogen Receptor/ERR HSP Autophagy Apoptosis	Cancer
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 µM and 1.8 µM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis.Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse.

HY-151465

HIF-1α-IN-4	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-4 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-4 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-4 can be used in the research of cancer.

HY-124958

NDMC101	NF-κB Dipeptidyl Peptidase	Metabolic Disease Inflammation/Immunology
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al.

HY-121508

(E/Z)-IT-603	NF-κB	Cancer Inflammation/Immunology
(E/Z)-IT-603 is a mixture of E-IT-603 and Z-IT-603 (IT-603). IT-603 is a c-Rel inhibitor with an IC₅₀ of 3 μM. IT-603 has anti-tumor activity. (E/Z)-IT-603 is a promising modulator of T-cell responses in the context of graft-versus-host disease (GVHD) and malignant diseases.

HY-N9965

2'-Fucosyllactose 2'-FL	TNF Receptor Interleukin Related	Infection Inflammation/Immunology
2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines.

HY-11062

Icilin AG-3-5	TRP Channel	Inflammation/Immunology Neurological Disease
Icilin (AG-3-5) is a super-agonist of the transient receptor potential M8 (TRPM8) ion channel. Icilin activates TRPM8 in EGTA in a dose-dependent manner (EC₅₀=1.4 μM). Icilin is a “super-cooling agent”. Icilin attenuates autoimmune neuroinflammation through modulation of the T-cell response.

HY-N7634

Tectol	Farnesyl Transferase Parasite	Cancer Infection
Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM. Tectol is a farnesyltransferase (FTase) inhibitor with IC₅₀s of 2.09 and 1.73 μM for human and T. brucei FTase, respectively. Tectol inhibits drug-resistant strain of P. falciparum (FcB1) with an IC₅₀ of 3.44 μM.

HY-130723

AMPK activator 2	AMPK	Cancer
AMPK activator 2 (compound 7a), a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549).

HY-146132

EGFR-IN-55	EGFR	Cancer
EGFR-IN-55 (Compound 8a) is a potent EGFR inhibitor with IC₅₀ values of 70 nM and 3.9 nM against EGFR^WT and EGFR^L858R/T790M, respectively. EGFR-IN-55 arrests NCI-H1975 cells in G0/G1 phase and shows anticancer activity.

HY-14171

Bexarotene LGD1069	RAR/RXR Autophagy	Cancer
Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC₅₀s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC₅₀ >10000 nM). Bexarotene can be used for the research of cutaneous T-cell lymphoma.

HY-P1432A

K-(D-1-Nal)-FwLL-NH2 TFA	GHSR
K-(D-1-Nal)-FwLL-NH2 TFA is a high affinity and potent ghrelin receptor inverse agonist (K_i values are 4.9 and 31 nM in COS7 and HEK293T cells, respectively). K-(D-1-Nal)-FwLL-NH2 blocks ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.

HY-130616

EGFR-IN-11	EGFR Apoptosis	Cancer
EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1.

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs.

HY-112616

NAMPT inhibitor-linker 2	NAMPT Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC₅₀s of <7 pM and 40 pM, respectively.

HY-15814

HG-7-85-01	Bcr-Abl PDGFR c-Kit Src JAK Apoptosis	Cancer
HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC₅₀s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC₅₀>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression.

HY-P99573

Tebotelimab MGD-013	PD-1/PD-L1	Cancer Inflammation/Immunology
Tebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity.

HY-149830

PD-L1-IN-2	PD-1/PD-L1	Cancer
PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research.

HY-131296

5-A-RU-PABC-Val-Cit-Fmoc	Others	Inflammation/Immunology
5-A-RU-PABC-Val-Cit-Fmoc is the proagent of 5-A-RU. 5-A-RU, a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways.

HY-116090

Conoidin A	Parasite	Infection Neurological Disease Cardiovascular Disease
Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC₅₀ of 23 µM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII). Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease.

HY-19356

Rocaglamide Roc-A	NF-κB HSP Eukaryotic Initiation Factor (eIF)	Cancer
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.

HY-118858

UCPH-102	Others	Cancer Neurological Disease
UCPH-102 is a highly selective EAAT1 inhibitor with an IC₅₀ of 0.43 µM. UCPH-102 exhibits a specific anti-proliferative effect on T-ALL cells. UCPH-102 also shows good blood-brain permeability, which can be used in studies of amyotrophic lateral sclerosis, Alzheimer’s disease, chronic pain and obsessive compulsive disorder.

HY-18303

AMG-47a	Src VEGFR p38 MAPK JAK	Inflammation/Immunology
AMG-47a is a potent and orally active lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, with an IC₅₀ of 0.2 nM. AMG-47a also inhibits VEGF2, p38α, Jak3 and MLR and IL-2 with IC₅₀s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively. AMG-47a has anti-inflammatory activity.

HY-115489

GGTI-286	Ras	Cancer
GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM.

HY-P99575

Tarlatamab AMG-757	Notch	Cancer Inflammation/Immunology
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

HY-102011A

BMS-1166 hydrochloride	PD-1/PD-L1	Cancer Inflammation/Immunology
BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.

HY-146335

CLK1/4-IN-1	CDK	Cancer
CLK1/4-IN-1 (compound 31) is a potent and selective Clk1 and Clk4 inhibitor with an IC₅₀ value of 9.7 nM and 6.6 nM, respectively. CLK1/4-IN-1 has growth inhibitory activities against T24 cancer cells with GI₅₀ of 1.1 μM. CLK1/4-IN-1 can be used for researching anticancer.

HY-P99762

Obrindatamab MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs.

HY-129624A

Bisindolylmaleimide VIII acetate Ro 31-7549 acetate; Bis VIII acetate	PKC Apoptosis	Cancer Inflammation/Immunology
Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC₅₀ of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC₅₀s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-β_I, PKC-β_II, PKC-γ, PKC-ε, respectively. Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases.

HY-150569

BCR-ABL-IN-6	Bcr-Abl	Cancer
BCR-ABL-IN-6 (9h) is a selective Bcr-Abl kinase inhibitor with IC₅₀s of 4.6 and 227 nM for Bcr-Abl^WT and Bcr-Abl^T3151 respectively. BCR-ABL-IN-6 inhibits Bcr-Abl kinase with strong affinity inside the cells with an EC₅₀ of 14.6 nM. BCR-ABL-IN-6 is an imatinib derivative which can be used for research of chronic myelogenous leukemia.

HY-113953

Z-Asp-CH2-DCB	Caspase Apoptosis	Inflammation/Immunology
Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development.

HY-108944

LYP-IN-1	SHP2 Phosphatase	Inflammation/Immunology
LYP-IN-1 is a potent, selective and specific LYP inhibitor with a K_i and an IC₅₀ of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC₅₀=5 μM) and SHP2 (IC₅₀=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders.

HY-151466

HIF-1α-IN-5	HIF/HIF Prolyl-Hydroxylase Monoamine Oxidase	Cancer
HIF-1α-IN-5 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer.

HY-117433S

4-Hydroperoxy Cyclophosphamide-d4	DNA Alkylator/Crosslinker Apoptosis Reactive Oxygen Species Drug Metabolite	Inflammation/Immunology
4-Hydroperoxy Cyclophosphamide-d₄ is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders[1][2].

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL).

HY-100707

IC 86621	DNA-PK Apoptosis	Cancer Inflammation/Immunology
IC 86621 is a potent DNA-dependent protein kinase (DNA-PK) inhibitor, with an IC₅₀ of 120 nM. IC 86621 also acts as a selective and reversible ATP-competitive inhibitor.IC 86621 inhibits DNA-PK mediated cellular DNA double-strand break (DSB) repair (EC₅₀=68 µM). IC 86621 increases DSB-induced antitumor activity without cytotoxic effects. IC 86621 can protects rheumatoid arthritis (RA) T cells from apoptosis.

HY-115463

EB-3D	AMPK Apoptosis	Cancer
EB-3D is a potent and selective choline kinase α (ChoKα) inhibitor, with an IC₅₀ of 1 μM for ChoKα1. EB-3D exerts effects on ChoKα expression, AMPK activation, apoptosis, endoplasmic reticulum stress and lipid metabolism. EB-3D exhibits a potent antiproliferative activity in a panel of T-leukemia cell lines. Anti-cancer activity.

HY-115489A

GGTI-286 TFA	Ras	Cancer
GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM.

HY-126251

CDK9-IN-7	CDK Apoptosis	Cancer
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC₅₀=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.

HY-10261E

(R)-Afatinib (R)-BIBW 2992	EGFR c-Met/HGFR p38 MAPK	Cancer
(R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.

HY-114170

ML604440	Proteasome	Inflammation/Immunology
ML604440 is a specific and cell-permeable Proteasome β1i (LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor.

HY-149837

PRO-F	Fluorescent Dye	Inflammation/Immunology
PRO-F is a photoactivable H₂S donor with ROS scavenging ability. PRO-F can be activated by light to produce fluorescent signal, for real-time tracking of released H₂S. PRO-F activation doesn’t consume endogenous substances. deliver H₂S in an intracellular environment to protect cells from excessive reactive oxygen species (ROS) induced damage. PRO-F shows enhancement on chronic wound healing, researched in diabetic models as well.

HY-144680

BLU-945	EGFR	Cancer
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).

HY-150746

ODN 24991	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24991, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a TLR3, TLR7 and TLR9 (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 24991 disrupts TLR3-, TLR7- and TLR9-mediated immune cell immune responses. ODN 24991 sequence: 5'-C-C-T-G-G-C-c7rGm-G-G-G-3'.

HY-143472

PI3Kδ-IN-11	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-11 is a highly potent and selective PI3Kδ inhibitor with IC₅₀ value of 27.5 nM. PI3Kδ-IN-11 dose-dependently blocks the activity of PI3K/Akt pathway. PI3Kδ-IN-11 can be used for researching B or T cell-related malignancies.

HY-144437

ALK5-IN-9	TGF-β Receptor	Cancer
ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC₅₀ values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease.

HY-P1997

Ferrichrome Iron-free Desferrichrome; DFC; N-Desferriferrichrome	Biochemical Assay Reagents	Others
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.

HY-145858

Chalcones A-N-5	Ferroptosis	Cancer
Chalcones A-N-5 is a trihydroxy chalcone derivative compound. Chalcones A-N-5 doesn’t show cytotoxicity at the concentration lower than 100 µM (with IC₅₀ > 1 mM), but has a significant effect on promoting cell proliferation. Chalcones A-N-5 potentially promotes neuronal cell growth in the damaged brain tissue. Chalcones A-N-5 also inhibits ferroptosis induced by RSL or erastin and reduces the lipid peroxidation levels induced by Aβ1-42 protein aggregation. Chalcones A-N-5 is a promising molecular skeleton candidate for further development of lead compound for in vivo test to research AD.

HY-144746

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of PD-1/PD-L1 with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases.

HY-108601A

Ro 32-0432 hydrochloride	PKC	Inflammation/Immunology Neurological Disease
Ro 32-0432 hydrochloride is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC₅₀ values of Ro 32-0432 hydrochloride for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. Ro 32-0432 hydrochloride is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. Ro 32-0432 hydrochloride prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research.

HY-146349

PROTAC EGFR degrader 4	PROTACs EGFR Autophagy	Cancer
PROTAC EGFR degrader 4 is a potent PROTAC targeting mutant EGFR.PROTAC EGFR degrader 4 induces EGFR^del19 and EGFR^L858R/T790M degradation with DC₅₀s of 0.51 and 126 nM, respectively. PROTAC EGFR degrader 4 significantly inhibits growth of HCC827 and H1975 cell lines with IC₅₀s of 0.83 and 203.1 nM, respectively. Induced EGFR degradation is related to autophagy.

HY-117935

GGTI-286 hydrochloride	Ras	Cancer
GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM.

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (K_d=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.

HY-132866

YS-370	P-glycoprotein	Cancer
YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity.

HY-116330

Hyperforin	Calcium Channel TRP Channel	Inflammation/Immunology Neurological Disease
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca²⁺ levels by activating Ca²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.

HY-B0847S1

Propiconazole-d3 nitrate	Fungal Reactive Oxygen Species	Infection
Propiconazole-d₃ (nitrate) is the deuterium labeled Propiconazole nitrate. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 µM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 µg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS).

HY-153128

DOCK2-IN-1	DOCK	Inflammation/Immunology
DOCK2-IN-1 (compound 3), a CPYPP (HY-110100) analogue, is an inhibitor of DOCK2 as well (IC₅₀=19.1 μM). DOCK2-IN-1 binds to DOCK2 DHR-2 domain in a reversible manner to inhibits its catalytic activity. DOCK2-IN-1 blocks the activation of both chemokine receptor- and antigen receptor-mediated Rac in lymphocytes. DOCK2-IN-1 significantly suppresses chemotactic response and T cell activation.

HY-B0847S

Propiconazole-d7	Fungal Reactive Oxygen Species	Infection
Propiconazole-d₇ is the deuterium labeled Propiconazole. Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 µM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 µg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS)[1].

HY-P99032

Monalizumab	Checkpoint Kinase (Chk) IFNAR	Cancer Inflammation/Immunology
Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

HY-116330A

Hyperforin dicyclohexylammonium salt Hyperforin DCHA	TRP Channel Calcium Channel	Neurological Disease
Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca²⁺ levels by activating Ca²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.

HY-100586

Ibuprofen L-lysine (±)-Ibuprofen L-lysine	COX Apoptosis Parasite	Cancer Infection Inflammation/Immunology
Ibuprofen ((±)-Ibuprofen) L-lysine is a potent orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen L-lysine inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen L-lysine is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen L-lysine can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.

HY-78131

Ibuprofen (±)-Ibuprofen	COX Apoptosis Parasite	Cancer Infection Inflammation/Immunology Neurological Disease
Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.

HY-78131C

Ibuprofen sodium (±)-Ibuprofen sodium	COX Apoptosis Parasite	Cancer Infection Inflammation/Immunology Neurological Disease
Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen sodium inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen sodium is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen sodium can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.

HY-112608

CHMFL-PI3KD-317	PI3K	Cancer
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC₅₀ of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC₅₀, 62.6 nM), PI3Kβ (IC₅₀, 284 nM), PI3Kγ (IC₅₀, 202.7 nM), PIK3C2A (IC₅₀, >10000 nM), PIK3C2B (IC₅₀, 882.3 nM), VPS34 (IC₅₀, 1801.7 nM), PI4KIIIA (IC₅₀, 574.1 nM) and PI4KIIIB (IC₅₀, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC₅₀ of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells.

HY-112371

(S)-CR8	CDK	Cancer
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM).

HY-131187

BMS-1166-N-piperidine-COOH	Ligands for Target Protein for PROTAC	Cancer
BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1. BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.

HY-15898

Y-320	Interleukin Related Apoptosis	Cancer Inflammation/Immunology
Y-320 is a potent, orally active phenylpyrazoleanilide immunomodulator. Y-320 inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC₅₀ values of 20 to 60 nM. Y-320 enhances TP53, DMD, and COL17A1 PTC readthrough by G418 and increases cellular protein levels and protein synthesis. Y-320 concomitants use of with a low dose of Paclitaxel (HY-B0015) significantly sensitized multidrug resistance (MDR) tumors by inducing G2/M phase arrest and apoptosis. Y-320 can be used for research of rheumatoid arthritis (RA) and cancer.

HY-W251428

Phosphatidylglycerols (egg) (sodium salt)	Biochemical Assay Reagents	Others
Phosphatidylglycerol is a naturally occurring anionic phospholipid that is a component of plant, animal and bacterial cell membranes. It is present in prokaryotes and eukaryotes less than phosphatidylethanolamine, and in eukaryotes less than phosphatidylcholine. It is formed by the reaction between CDP-diglyceride and L-α-glycerol 3-phosphate followed by dephosphorylation and is the metabolic precursor of cardiolipin. Phosphatidylglycerols containing polyunsaturated and monounsaturated fatty acyl chains inhibit and promote the proliferation of murine keratinocytes, respectively. Phosphatidylglycerol is the second-largest lipid component of mammalian lung surfactant, accounting for 10% of lipids, and has reduced levels of pulmonary surfactant in infants with respiratory distress syndrome. Phosphatidylglycerol (egg) is a mixture of phosphatidylglycerols isolated from eggs with various fatty acyl groups at the sn-1 and sn-2 positions. References: [1]. Ohtsuka, T., Nishijima, M., and Akamatsu, Y. Phosphatidylglycerol phosphate synthase-deficient somatic mutants with impaired phosphatidylglycerol and cardiolipin biosynthesis J. Biol. Chemical. 268(30), 22908-22913 (1993).[2]. Furse, S. Are phosphatidylglycerols essential for terrestrial life? J. Chemistry. biology. 10(1), 1-9 (2016).[3]. Xie, D., Seremwe, M., Edwards, JG, et al. Different effects of different phosphatidylglycerols on the proliferation of mouse keratinocytes PLoS One 9(9), e107119 (2014).

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

430 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 430 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L040

Anti-diabetic Compound Library

648 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 648 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type

HY-110251A

DFHBI-2T	Fluorescent Dyes/Probes
DFHBI-2T is a membrane-permeable RNA aptamers-activated fluorescence probe (ex/em=500 nm/523 nm). DFHBI-2T is used to image RNA in live cells. Storage: protect from light.

HY-110251

DFHBI-1T	Fluorescent Dyes/Probes
DFHBI-1T is a membrane-permeable RNA aptamers-activated fluorescence probe (ex/em=472 nm/507 nm). DFHBI-1T binds to RNA aptamers (Spinach, Spinach2, iSpinach, and Broccoli) and causes specific fluorescence and lower background fluorescence. DFHBI-1T is used to image RNA in live cells. Storage: protect from light.

HY-15629

HOE 32020

DNA Stain

HOE 32020 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15625

Hoechst 33258 analog 3

DNA Stain

Hoechst 33258 analog 3 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15559

Hoechst 33342

bisBenzimide H 33342; HOE 33342

DNA Stain

Hoechst 33342 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15562

HOE 32021

DNA Stain

HOE 32021 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15561

HOE-S 785026

meta-Hoechst

DNA Stain

HOE-S 785026 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15559A

Hoechst 33342 trihydrochloride

bisBenzimide H 33342 trihydrochloride; HOE 33342 trihydrochloride

DNA Stain

Hoechst 33342 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15619

Hoechst S 769121

Nuclear yellow

DNA Stain

Hoechst S 769121 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15560

Hoechst 34580

HOE 34580

DNA Stain

Hoechst 34580 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15630A

Hoechst 33342 analog 2 trihydrochloride

DNA Stain

Hoechst 33342 analog 2 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15630

Hoechst 33342 analog 2

DNA Stain

Hoechst 33342 analog 2 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15563

HOE 33187

DNA Stain

HOE 33187 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15631

Hoechst 33258 analog 6

DNA Stain

Hoechst 33258 analog 6 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15558A

Hoechst 33258 trihydrochloride

bisBenzimide H 33258 trihydrochloride; H 33258 trihydrochloride

DNA Stain

Hoechst 33258 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15561B

HOE-S 785026 trihydrochloride

meta-Hoechst trihydrochloride

DNA Stain

HOE-S 785026 trihydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15560B

Hoechst 34580 tetrahydrochloride

HOE 34580 tetrahydrochloride

DNA Stain

Hoechst 34580 tetrahydrochloride is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15626

ortho-iodoHoechst 33258

DNA Stain

ortho-iodoHoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15627

Hoechst 33342 analog

DNA Stain

Hoechst 33342 analog is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15623

Hoechst 33258 analog

DNA Stain

Hoechst 33258 analog is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15622

meta-iodoHoechst 33258

DNA Stain

meta-iodoHoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15628

Hoechst 33258 analog 5

DNA Stain

Hoechst 33258 analog 5 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15624

Hoechst 33258 analog 2

DNA Stain

Hoechst 33258 analog 2 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15632

para-iodoHoechst 33258

DNA Stain

para-iodoHoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

HY-15558

Hoechst 33258

bisBenzimide H 33258; H 33258

DNA Stain

Hoechst 33258 is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. Hoechst binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity Therefore,Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. Storage: Keep away from light.

Cat. No.	Product Name	Type

HY-141582

Ceramide 3

N-Stearoyl phytosphingosine

Biochemical Assay Reagents

C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation.

HY-E70016

Terminal deoxyribonucleotidyltransferase TdT	Enzyme
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells.

HY-153233

CD19 car mRNA-LNP

LNPs for Drug Delivery

CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-153234

CD19 car circRNA-LNP

LNPs for Drug Delivery

CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-P2724

Purine nucleoside phosphorylase

PNP

Enzyme

Purine nucleoside phosphorylase is a key enzyme in purine metabolism, which is involved in the purine rescue pathway. The deficiency of Purine nucleoside phosphorylase resulted in impaired T cell function. In the presence of inorganic orthophosphate as the second substrate, Purine nucleoside phosphorylase catalyzes the breaking of the glycosidic bond between ribose and deoxyribonucleoside to generate purine base and ribose (deoxyribose) -1-phosphate.

HY-W251428

Phosphatidylglycerols (egg) (sodium salt)

Biochemical Assay Reagents

Phosphatidylglycerol is a naturally occurring anionic phospholipid that is a component of plant, animal and bacterial cell membranes. It is present in prokaryotes and eukaryotes less than phosphatidylethanolamine, and in eukaryotes less than phosphatidylcholine. It is formed by the reaction between CDP-diglyceride and L-α-glycerol 3-phosphate followed by dephosphorylation and is the metabolic precursor of cardiolipin. Phosphatidylglycerols containing polyunsaturated and monounsaturated fatty acyl chains inhibit and promote the proliferation of murine keratinocytes, respectively. Phosphatidylglycerol is the second-largest lipid component of mammalian lung surfactant, accounting for 10% of lipids, and has reduced levels of pulmonary surfactant in infants with respiratory distress syndrome. Phosphatidylglycerol (egg) is a mixture of phosphatidylglycerols isolated from eggs with various fatty acyl groups at the sn-1 and sn-2 positions. References: [1]. Ohtsuka, T., Nishijima, M., and Akamatsu, Y. Phosphatidylglycerol phosphate synthase-deficient somatic mutants with impaired phosphatidylglycerol and cardiolipin biosynthesis J. Biol. Chemical. 268(30), 22908-22913 (1993).[2]. Furse, S. Are phosphatidylglycerols essential for terrestrial life? J. Chemistry. biology. 10(1), 1-9 (2016).[3]. Xie, D., Seremwe, M., Edwards, JG, et al. Different effects of different phosphatidylglycerols on the proliferation of mouse keratinocytes PLoS One 9(9), e107119 (2014).

Cat. No.	Product Name	Target	Research Area

HY-P3638

Binetrakin	Peptides	Inflammation/Immunology
Binetrakin (Interleukin 4 (human)) is a T lymphocyte-derived pleiotrophic cytokine that affects a variety of cell types including B cells and T cells. Binetrakin induces differentiation of naive helper T cells (Th0 cells) to Th2 cells. Binetrakin can be used for the research of many biological.

HY-P1089

Cytochrome c-pigeon (88-104) PCC 88-104	Peptides	Inflammation/Immunology
Cytochrome c-pigeon (88-104) (PCC 88-104) has full stimulatory activity for pigeon cytochrome c-primed T cells from B10.A mice. The I-E^k-restricted T cell response to Cytochrome c pigeon (pcyt c) is specific for the COOH-terminal sequence 88-104.

HY-W019721

Cyclosporin D	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A. Cyclosporin A is a potent immunosuppressant agent, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc).

HY-P2511

Insulin β Chain Peptide (15-23)	Peptides	Metabolic Disease
Insulin β Chain Peptide (15-23), also known as INS, is an insulin-derived peptide recognized by islet-associated T cells. The Insulin β Chain Peptide (15-23) tetramer stained the INS-reactive CTL clone G9C8, but neither this tetramer nor the negative control tetramer (TUM) stained the splenic CD8+ T cells from NOD or 8.3-TCRαβtransgenic NOD mice.

HY-105063

DiaPep277	Peptides	Metabolic Disease Inflammation/Immunology
DiaPep277 is a 24 amino acid peptide derived from positions 437-460 in HSP60. DiaPep277 arrests the progression of β-cell destruction in NOD mice. DiaPep277 has an immune modulatory effect on diabetogenic T cells in animal models of diabetes.

HY-P3554

Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl	HIV	Infection
Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl (compound (CPF(LL)) is an HIV-1 inhibitor. Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl interacts with gp120 to block gp120 binding to CD4 and preserve CD4-dependent T cell function.

HY-P2561

Influenza Matrix Protein (61-72)	Influenza Virus	Infection Inflammation/Immunology
Influenza Matrix Protein (61-72) is a peptide fragment derived from matrix protein of influenza viruses, corresponds to amino acids 61-72. Influenza Matrix Protein (61-72) is a specific epitope which can induce CD4⁺ T-cell response.

HY-P3644

EEKLIVVAF
Peptides Cancer

EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5.

HY-P3719

MOG peptide (35-55)	Peptides	Inflammation/Immunology
MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4⁺ T cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model.

HY-P3742

Tyrosinase (192-200), human mouse	Peptides	Cancer
Tyrosinase (192-200), human mouse is a nonapeptide. Tyrosinase (192-200), human mouse can be recognized by cytolytic T cell (CTL) on the HLA-B44 molecule. Tyrosinase (192-200), human mouse can be used in research of melanoma associated cancers.

HY-113893

β-Interleukin I (163-171), human	Peptides	Inflammation/Immunology
β-Interleukin I (163-171), human, an immunostimulatory fragment of human IL-1β peptide, is a T cell activator. β-Interleukin I (163-171), human is not an IL-1R-binding domain of IL-1β. β-Interleukin I (163-171), human is a potent adjuvant that enhances the immune response in a variety of exptl. situations.

HY-P2560

LCMV GP (61-80)	Arenavirus	Infection Inflammation/Immunology
LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4⁺ T-cell response.

HY-P3817

Des-[Gly77,His78] Myelin Basic Protein (68-84), bovine	Peptides	Neurological Disease
Des-[Gly77,His78] Myelin Basic Protein (68-84) is a 68-84 sequence fragment of guinea pig myelin basic protein (GPMBP). Des-[Gly77,His78] Myelin Basic Protein (68-84) regulates functionally diverse encephalitogenic and proliferative activities of experimental autoimmune encephalomyelitis (EAE)-associated T cells.

HY-P4046

HBV Seq2 aa:179-186	HIV	Inflammation/Immunology
HBV Seq2 aa:179-186 serve as effective motifs for CTL response in H-2b system after in vitro restimulation of the primed T cells. HBV Seq2 aa:179-186 is a novel epitope identified on the surface antigen of hepatitis B virus.

HY-P3736

Myelopeptide-2 MP-2	Interleukin Related	Cancer
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.

HY-P1698

Reltecimod AB-103	Bacterial CD28	Infection Inflammation/Immunology
Reltecimod (AB-103) is a *T-cell-specific surface glycoprotein CD28 (TP44)* antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).

HY-P3723

MBP (83-99)	Peptides	Inflammation/Immunology
MBP (83-99) is a MBP-specific T cell lines recognizing the immunodominant epitope. MBP (83-99) induces proliferation and IFN-γ secreting of T cells.

HY-P0310

SV40 large T antigen NLS
Peptides Infection

SV40 large T antigen NLS is from Large T antigen residue 47 to 55, enables protein import into cell nucleus.

HY-P2514

TET 830 modified/T-helper epitope from tetanus toxoid	Peptides	Inflammation/Immunology
TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope from tetanus toxoid. TET 830 modified/T-helper epitope from tetanus toxoid induces T-cells responses and is used as a helper peptide in vaccinations.

HY-P2455

LLO (91-99) Listeriolysin O (91-99)	Bacterial	Inflammation/Immunology
LLO (91-99) (Listeriolysin O (91-99)), an exotoxin, is a class I MHC-restricted T-cell epitopes of listeriolysin (LLO). LLO (91-99) is an essential antigen for induction of T-cell mediated immunity in vivo.

HY-P1822

BDC2.5 mimotope 1040-31	Peptides	Metabolic Disease
BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg⁺T cells.

HY-P1822A

BDC2.5 mimotope 1040-31 TFA	Peptides	Metabolic Disease
BDC2.5 mimotope 1040-31 TFA, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg⁺T cells.

HY-P0287

QL9
Peptides Inflammation/Immunology

QL9 (QLSPFPFDL) is a high-affinity alloantigen for the 2C T cell receptor (TCR).

HY-P2251

T-peptide	HIV Microtubule/Tubulin	Cancer Infection Inflammation/Immunology
T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.

HY-P0287A

QL9 TFA
Peptides Inflammation/Immunology

QL9 (QLSPFPFDL) TFA is a high-affinity alloantigen for the 2C T cell receptor (TCR).
HY-P1404

R8-T198wt
Pim Cancer

R8-T198wt is a cell-permeable carboxyl-terminal p27^Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.

HY-P2525

GAD65 (206-220)	Peptides	Inflammation/Immunology
GAD65 (206-220) is glutamic acid decarboxylase (GAD) 65-derived peptide, corresponding to residues 180-188. GAD65 is presented to T cells in association with I-Ag7 MHC class II molecules and a major pancreatic antigens targeted by self-reactive T cells in type I diabetes mellitus.

HY-P1811

Iα52	Peptides	Inflammation/Immunology
Iα52 is a naturally processed peptide encompassed the residues 52-68 of the murine I-Eα chain and may contribute to selection of immature T cells.

HY-P4628

TPNQRQNVC
LRH-1 peptide
Peptides Inflammation/Immunology

TPNQRQNVC is a nonapeptide and is the epitope of HLA-B0702. TPNQRQNVC induces a CD8+ T cell immune response.

HY-P3410

Trichomide A	SHP2 Phosphatase	Inflammation/Immunology
Trichomide A is a potent activator of SHP2. Trichomide A is a natural cyclodepsipeptide. Trichomide A displays immunosuppressive activity against activated T lymphocyte–mediated immune responses in Con A-activated T cells. Trichomide A have the potential for the research of immune-related skin diseases.

HY-P1430

11R-VIVIT	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT can be used for the research of podocyte and diabetic nephropathy.

HY-P0260

p2Ca
Peptides Inflammation/Immunology

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of *B cell* lymphoma 6 (BCL6) with an IC₅₀** of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of *B cell* lymphoma 6 (BCL6), with an IC₅₀** of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.

HY-P1430A

11R-VIVIT TFA	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy.

HY-125486

Reversin 121	P-glycoprotein	Cancer
Reversin 121 is a P-glycoprotein inhibitor. Reversin 121 increases the ATPase activity of MDR1. Reversin 121 reverses P-glycoprotein-mediated multidrug resistance. Reversin 121 can be used in the research of cancers.

HY-P1877

SV40 T-Ag-derived NLS peptide
Peptides Cancer

SV40 T-Ag-derived NLS peptide is a nuclear localization signal DNA tagged to this peptide efficiently translocates into the cell nucleus.

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of *B cell* lymphoma 6 (BCL6), with an IC₅₀** of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.

HY-P0286

OVA Peptide (323-339)	Peptides	Inflammation/Immunology
OVA Peptide (323-339) represents a T and B cell epitope of Ovalbumin (Ova), which is important in the generation and development of immediate hypersensitivity responses in BALB/c mice.

HY-P0085

Splenopentin diacetate	Peptides	Inflammation/Immunology
Splenopentin diacetate is a synthetic immunomodulating pentapeptide corresponding to the residues 32-36 of the splenic hormone splenin. Splenopentin diacetate influences both early T and B cell differentiation, to increase the number of antibody-forming cells in mice after gamma irradiation.

HY-N7122

Thymopentin	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).

HY-N7122A

Thymopentin acetate	Endogenous Metabolite	Cancer Inflammation/Immunology
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).

HY-P1736

Influenza HA (126-138)	Influenza Virus	Infection
Influenza HA (126-138) is a influenza virus hemagglutinin (HA) peptide comprising amino acids 126-138, induces thymic and peripheral T-cell apoptosis.

HY-P3747

Hemagglutinin (48-68)	Influenza Virus	Infection
Hemagglutinin (48-68) is the 48-68 fragment of influenza virus hemagglutinin. Hemagglutinin (48-68) can induce proliferation of the peptide specific T-cell clones.

HY-P0323

GP(33-41)	Arenavirus	Infection
GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2D^b molecules at the RMA-S (Db Kb) cell surface with a SC₅₀ of 344 nM.

HY-P0323A

GP(33-41) TFA	Arenavirus	Infection
GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2D^b molecules at the RMA-S (Db Kb) cell surface with a SC₅₀ of 344 nM.

HY-P1585

Gp100 (25-33), human Hgp100 (25-33)	Peptides	Inflammation/Immunology
Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. It is a 9-amino acid (AA) epitope restricted by H-2D^b and recognized by the T cells.

HY-P1910

BDC2.5 mimotope 1040-51
Peptides Metabolic Disease

BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice.

HY-P1585A

Gp100 (25-33), human TFA Hgp100 (25-33) (TFA)	Peptides	Cancer
Gp100 (25-33), human TFA (Hgp100 (25-33) TFA) is the amino acids 25-33 fragment of the human melanoma antigen. It is a 9-amino acid (AA) epitope restricted by H-2D^b and recognized by the T cells.

HY-P3315

Onilcamotide RV001	Peptides	Cancer Inflammation/Immunology
Onilcamotide (RV001) is a C-terminal peptide of RhoC protein. Onilcamotide is a cancer vaccine and has potential immunomodulating and antineoplastic activities.

HY-P1052A

Myelin Basic Protein(87-99) TFA	Peptides	Inflammation/Immunology
Myelin Basic Protein(87-99) TFA is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) TFA causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS).

HY-P1914

NY-BR-1 p904 (A2)
Peptides Cancer

NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1.

HY-P1771

OVA G4 peptide	Peptides	Inflammation/Immunology
OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.

HY-P1771A

OVA G4 peptide TFA	Peptides	Inflammation/Immunology
OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.

HY-P4667

VLHDDLLEA	Peptides	Metabolic Disease
VLHDDLLEA is a peptide that can be isolated from the MHC complex HLA-A0201 molecule. VLHDDLLEA can be recognized by HLA-A0201-restricted cytotoxic T cells (CTLs). VLHDDLLEA can be used for research on graft versus host disease (GvHD).

HY-P3444

CD31 PECAM-1	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation^-.

HY-P1566

MPG, HIV related	HIV	Infection
MPG, HIV related is 27-aa peptide, derived from both the nuclear localisation sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41 and is a potent delivery agent for the generalised delivery of nucleic acids and of oligonucleotides into cultured cells.

HY-P3444A

CD31 TFA PECAM-1 TFA	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation^-.

HY-106374

Elpamotide	Peptides	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer.

HY-P4135

FITC-LC-Antennapedia Peptide	Peptides	Others
FITC-LC-Antennapedia Peptide is a FITC labeled Antennapedia Peptide (HY-P0307). Antennapedia Peptide is a cellular-membrane permeable peptides (CPP). FITC-LC-Antennapedia Peptide has good penetration in 3T3 cell line, which was rapidly accumulated into nuclei.

HY-108741

Plecanatide	Guanylate Cyclase	Inflammation/Immunology
Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis.

HY-P1996

Tiplimotide NBI-5788	Peptides	Inflammation/Immunology Neurological Disease
Tiplimotide (NBI-5788) is an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP). Tiplimotide can selectively reduce the production of inflammatory cytokines by pathogenic T-cells. Tiplimotide can be used for the research of multiple sclerosis (MS).

HY-P1854

β-Amyloid (1-9)	Amyloid-β	Neurological Disease
β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .

HY-P2479

Peripheral Myelin Protein P2 (53-78), bovine	Peptides	Inflammation/Immunology
Peripheral Myelin Protein P2 (53-78), bovine is derived from bovine peripheral myelin P2 protein amino acid residues 53-78. Peripheral Myelin Protein P2 (53-78), bovine is a T cell epitope for the induction of experimental autoimmune neuritis (EAN) in Lewis rats.

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-108741A

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis.

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function.

HY-P1432A

K-(D-1-Nal)-FwLL-NH2 TFA	GHSR
K-(D-1-Nal)-FwLL-NH2 TFA is a high affinity and potent ghrelin receptor inverse agonist (K_i values are 4.9 and 31 nM in COS7 and HEK293T cells, respectively). K-(D-1-Nal)-FwLL-NH2 blocks ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs.

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs.

HY-P2507

NY-ESO-1 (87-111)	Peptides	Cancer
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide sequence. NY-ESO-1 (87-111) binds to multiple HLA-DR and HLA-DP4 molecules, and stimulates Th1-type and Th-2/Th0-type CD4⁺ T cells when presented in the context of HLA-DR and HLA-DP4 molecules.

HY-P1997

Ferrichrome Iron-free Desferrichrome; DFC; N-Desferriferrichrome	Biochemical Assay Reagents	Others
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.

HY-P1240B

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate MOG (35-55) (acetate)	Peptides	Inflammation/Immunology Neurological Disease
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) acetate is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate produces a relapsing-remitting neurological disease with extensive plaque-like demyelination.

HY-P1240

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat MOG (35-55)	Peptides	Inflammation/Immunology Neurological Disease
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination.

HY-P1240A

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA MOG (35-55) (TFA)	Peptides	Inflammation/Immunology Neurological Disease
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) TFA is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA has encephalitogenic activity and induces T cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA produces a relapsing-remitting neurological disease with extensive plaque-like demyelination.

Cat. No.	Product Name

HY-K2014

PEI Transfection Reagent
MCE PEI Transfection Reagent is designed based on 25 kDa PEI. It has high-efficiency, low-toxicity, strong-stability, and is suitable for many cell types, such as HEK-293、HEK-293T、CHO-K1、COS-1、COS-7、NIH/3T3、Sf9、HepG2 and HeLa et, even some hard-to-transfect cells. It can also be applied to large-scale recombinant protein expression and virus production.

Cat. No.	Product Name	Target	Research Area

HY-P9947

Efalizumab	Integrin	Others
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation.

HY-P99390

Tepoditamab MCLA 117	CD3	Cancer
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research.

HY-P99790

Priliximab CEN 000029; cM-T412	Inhibitory Antibodies	Inflammation/Immunology
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4⁺ T cells. Priliximab can be used in research of rheumatoid arthritis (RA).

HY-P99302

Lulizumab Humanized Anti-CD28 Recombinant Antibody	CD28	Inflammation/Immunology
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling.

HY-P99024

Glofitamab RO7082859	CD20	Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.

HY-P99617

Fianlimab REGN3767	Inhibitory Antibodies	Cancer
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity.

HY-P99387

TSR-033	Inhibitory Antibodies	Cancer
TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity.

HY-P99382

Vopratelimab JTX 2011	Inhibitory Antibodies	Cancer Inflammation/Immunology
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the *Inducible CO-Stimulator of T cells* (ICOS)**. Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.

HY-P99570

Telazorlimab GBR-830	Inhibitory Antibodies	Inflammation/Immunology
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases.

HY-P9948

Alemtuzumab Campath-IH	Inhibitory Antibodies	Cancer
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52, a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes.

HY-P99259

Cabiralizumab FPA 008; Anti-Human CSF1R Recombinant Antibody	c-Fms	Cancer Inflammation/Immunology
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research.

HY-P99814

Pavurutamab AMG-701	CD3	Cancer Inflammation/Immunology
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-*B cell* maturation antigens (BCMA**). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).

HY-P99338

Tisagenlecleucel CTL019	Inhibitory Antibodies	Cancer Inflammation/Immunology
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma.

HY-P99680

Keliximab SB-210396; IDEC CE9.1	Interleukin Related	Cancer
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a K_i value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research.

HY-P99752

Nemvaleukin alfa ALKS 4230; RDB-1450	Interleukin Related	Cancer Inflammation/Immunology
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer.

HY-P99238

Rolinsatamab	Interleukin Related	Cancer Inflammation/Immunology
Rolinsatamab is a potent dual IL-4 and IL-13 inhibitor as a fully humanized bispecific monoclonal antibody. Rolinsatamab chimeric antigen receptor sequence T cell. Rolinsatamab can be used in research of immune disease.

HY-P99687

Latikafusp AMG 256	PD-1/PD-L1	Cancer
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.

HY-P99152

Muromonab	CD3	Cancer Inflammation/Immunology
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.

HY-P99962

Surzebiclimab BGB-A425	Inhibitory Antibodies	Cancer
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (K_D=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer.

HY-P9975

Theralizumab TGN1412	CD28	Inflammation/Immunology
Theralizumab (TGN1412) is a superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can be used for the research of rheumatoid arthritis.

HY-P99904

Siplizumab MEDI-507	CD2	Inflammation/Immunology
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells.

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines.

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research.

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research.

HY-P99827

Cobolimab TSR-022; GSK4069889	Tim3	Cancer
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC₅₀ value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells* to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.

HY-P99945

Revdofilimab ABBV-368	Orexin Receptor (OX Receptor)	Cancer Inflammation/Immunology
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells.

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.

HY-P99457

Balstilimab
AGEN2034
PD-1/PD-L1 Inflammation/Immunology

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1.

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Cancer Neurological Disease
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.

HY-P99033

Mosunetuzumab BTCT-4465A	CD20	Cancer Inflammation/Immunology
Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).

HY-P99253

Mogamulizumab KW-0761	CCR	Cancer Inflammation/Immunology
Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

HY-P99266

Zanolimumab Anti-Human CD4 Recombinant Antibody	Inhibitory Antibodies	Cancer Inflammation/Immunology
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.

HY-P99726

Maslimomab
Inhibitory Antibodies Inflammation/Immunology

Maslimomab is a murine monoclonal antibody targeting T-cell receptor. Maslimomab is an immunosuppressive agent.

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active humanized monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells.

HY-P99394

Talquetamab JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

HY-P9901

Ipilimumab MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.

HY-P99038

Odronextamab	CD20	Cancer Inflammation/Immunology
Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells.

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).

HY-P99679

Izuralimab
PD-1/PD-L1 Cancer Inflammation/Immunology

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.

HY-P99202

Vibostolimab	Inhibitory Antibodies	Cancer
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.

HY-P99280

Bimekizumab Anti-Human IL17A/IL-17F Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.

HY-P99408

Oxelumab R 4930; huMAb OX 40L; Ro 49-89991	Interleukin Related	Inflammation/Immunology
Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma.

HY-P99430

Alnuctamab EM901; CC-93269	Inhibitory Antibodies	Inflammation/Immunology
Alnuctamab (EM901) is an asymmetric 2-arm, humanized IgG T-cell engager (TCE). Alnuctamab can be used for immune research.

HY-P99651

Grisnilimab setaritox WT1-RTA	Inhibitory Antibodies	Cancer
Grisnilimab setaritox (WT1-RTA), is an antihuman T cell antibody (anti-CD7) conjugating with ricin A chain (RTA). RTA is a 30-kDa peptide capable of rapidly in activating ribosomal 60S subunits. Grisnilimab setaritox is cytotoxic to CEM (T-lymphoblastic leukemia) cells in vitro with an ID₅₀ of 53 pM. Grisnilimab setaritox also improves leukemic meningitis model in rhesus monkeys.

HY-P99508

Tamgiblimab IBI939	Inhibitory Antibodies	Cancer
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects.

HY-P99369

Lacutamab IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)	Inhibitory Antibodies	Cancer
Lacutamab (IPH4102) is a humanized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma.

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.

HY-P99051

Tinurilimab BAY 1834942	Inhibitory Antibodies	Cancer Inflammation/Immunology
Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.

HY-P99763

Ociperlimab BGB-A1217	Inhibitory Antibodies	Cancer
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (K_D = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer.

HY-P99434

Amlitelimab KY1005; SAR445229	Inhibitory Antibodies	Inflammation/Immunology
Alvircept sudotox is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Alvircept sudotox inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis.

HY-P99908

Efineptakin alfa NT-17	Interleukin Related	Cancer
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4⁺ and CD8⁺ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research.

HY-P99420

Acazicolcept ALPN-101	CD28	Inflammation/Immunology
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual *inducible T cell* costimulator (ICOS)/CD28** antagonist. Acazicolcept has anti-inflammatory activities.

HY-P99521

Vibecotamab XmAb14045	CD3	Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies.

HY-P9986

Tiragolumab	Inhibitory Antibodies	Cancer Inflammation/Immunology
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lung cancer.

HY-P99040

Onvatilimab JNJ-61610588	PD-1/PD-L1	Cancer
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-*VISTA (V-domain Ig Suppressor of T-cell* Activation)** monoclonal antibody. Onvatilimab has an anti-tumor activity.

HY-P99776

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.

HY-P99759

Nogapendekin alfa	Interleukin Related	Cancer Inflammation/Immunology
Nogapendekin alfa is a superagonist of IL-15. Nogapendekin alfa promotes the proliferation and viability of immune cells. Nogapendekin alfa combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form ALT-803, an IL-15 cytokine antibody fusion protein. ALT-803 reduces tumor burden by activation of NK cells and CD8⁺ T cells.

HY-P99717

Lulizumab pegol BMS-931699	CD28	Inflammation/Immunology
Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease.

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25 nM. Envafolimab has the potential for the research of solid tumors.

HY-P99055

Urelumab	Inhibitory Antibodies	Cancer Inflammation/Immunology
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab. Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL).

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively.

HY-P99565

Tengonermin ARENEGYR; NGR-TNF; NGR-hTNF	TNF Receptor	Cancer
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment.

HY-P99933

Eftilagimod alfa IMP321; LAG-3Ig	Inhibitory Antibodies	Cancer
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research.

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo.

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer Inflammation/Immunology
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity.

HY-P99052

Tislelizumab	PD-1/PD-L1	Cancer Inflammation/Immunology
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.

HY-P99354

Bavunalimab Anti-Human CTLA4xLAG3	CTLA-4	Cancer Inflammation/Immunology
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer.

HY-P99363

Feladilimab Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609	Inhibitory Antibodies	Cancer
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer.

HY-P99579

Tamtuvetmab AT-005; AT005	Inhibitory Antibodies	Cancer
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary.

HY-P99159

Ivuxolimab	Inhibitory Antibodies	Cancer
Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4⁺ and CD8⁺ T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity.

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4 Interleukin Related	Inflammation/Immunology
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

HY-P99660

Imvotamab IGM-2323	CD20 CD3	Cancer Inflammation/Immunology
Imvotamab (IGM-2323) is a CD20xCD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab is currently being developed for the treatment of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).

HY-P99327

Tregalizumab BT-061	Inhibitory Antibodies	Inflammation/Immunology
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies.

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.

HY-P99431

KY-1044 Alomfilimab; SAR 445256	Inhibitory Antibodies	Cancer Inflammation/Immunology
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response.

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Cancer Inflammation/Immunology
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-P99156

Relatlimab BMS-986016	Inhibitory Antibodies	Cancer
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC₅₀ value of 0.67 nM and LAG-3/FGL1 interaction with an IC₅₀ value of 0.019 nM. Relatlimab can be used in research of cancer.

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Cancer Inflammation/Immunology
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20⁺ non-Hodgkin lymphomas (NHL).

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).

HY-P99746

Murlentamab 3C23K; GM102	Inhibitory Antibodies	Cancer Inflammation/Immunology
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming.

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma.

HY-P99378

Neihulizumab ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)	Apoptosis	Inflammation/Immunology
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research.

HY-108829

Abatacept CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

HY-P99176

ATG-031	Inhibitory Antibodies	Cancer
ATG-031 is a humanised anti-CD24 monoclonal antibody. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the "don't eat me" signals that characterize the growth of many cancers. ATG-031 can be used in the study of haematological malignancies as well as solid tumours.

HY-P99836

Cudarolimab IBI101	Orexin Receptor (OX Receptor)	Cancer Inflammation/Immunology
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.

HY-P99573

Tebotelimab MGD-013	PD-1/PD-L1	Cancer Inflammation/Immunology
Tebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity.

HY-P99575

Tarlatamab AMG-757	Notch	Cancer Inflammation/Immunology
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

HY-P99762

Obrindatamab MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (K_d=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.

HY-P99032

Monalizumab	Checkpoint Kinase (Chk) IFNAR	Cancer Inflammation/Immunology
Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Cat. No.	Product Name	Target	Category

HY-W019721

Cyclosporin D	Nuclear Factor of activated T Cells (NFAT)	Structural Classification Natural Products Microorganisms Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A. Cyclosporin A is a potent immunosuppressant agent, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc).

HY-119347

Cirsilineol	IFNAR STAT	Flavonoids Flavones Phenols Monophenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Compositae Laburnum anagyroides Medic.
Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4⁺ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.

HY-129055

Isoeleutherin	Fungal	Quinones Naphthalene Quinones Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Iridaceae Eleutherine plicata Herb.
Isoeleutherin is a naphthopyran derivative isolated from E. americana Merr. Et Heyne with anti-fungal, anti-viral, and anti-tumor activities. Isoeleutherin plays an important role in selective modulation of T helper cell-mediated immune responses.

HY-113962

7α,25-Dihydroxycholesterol 7α,25-OHC	EBI2/GPR183 Endogenous Metabolite	Steroids Structural Classification Endogenous metabolite Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC₅₀=140 pM; K_d=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.

HY-101092

QS-21 Stimulon	NOD-like Receptor (NLR)	Triterpenes Terpenoids Structural Classification other families Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
QS-21, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21 stimulates Th2 humoral and Th1 cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells. QS-21 can activate the NLRP3 inflammasome with subsequent release of caspase-1 dependent cytokines, IL-1β and IL-18.

HY-N3796

Echinulin Echinuline	NF-κB	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Microorganisms
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to NF-κB activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent.

HY-N10295

Flavipin	Aryl Hydrocarbon Receptor	Phenols Polyphenols Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Microorganisms
Flavipin is an aryl hydrocarbon receptor (Ahr) agonist that induces the expression of Ahr downstream genes in mouse CD4⁺ T cells and CD11b⁺ macrophages. Flavipin inhibits the stabilizing function of Arid5a on Il23a 3′UTR, a newly identified target mRNA. Flavipin exhibits the DPPH free radical scavenging ability with IC₅₀ value of 7.2 μM, and has potent α-glucosidase inhibition with IC₅₀ value of 33.8 μM.

HY-N4053

Heraclenin	Nuclear Factor of activated T Cells (NFAT)	Coumarins Phenylpropanoids Structural Classification Umbelliferae Heracleum hemsleyanum Diels Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Heraclenin, a natural furanocoumarin, significantly inhibits T cell receptor-mediated proliferation in human primary T cells in a concentration-dependent manner by targeting nuclear factor of activated T-cells (NFAT).

HY-113636

Kazinol A	Others	Phenols Polyphenols Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2.

HY-N4010

Iriflophenone	Others	Phenols Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Thymelaeaceae Aquilaria sinensis Iridaceae Belamcanda chinensis (Linn.) Redouté
Iriflophenone, isolated from Aquilaria sinensis, stimulates MCF-7 and T-47D human breast cancer cells proliferation.

HY-N11648

Ganoderic acid T1	Apoptosis Caspase	Triterpenes Structural Classification Terpenoids Microorganisms Source classification
Ganoderic acid T1 is a deacetylated derivative of Ganoderic acid T. Ganoderic acid T1 attenuates antioxidant defense system and induces apoptosis of cancer cells. Ganoderic acid T1 decreases mitochondrial membrane potential and activates caspase-9 and caspase-3, to trigger apoptosis. Ganoderic acid T1 also increases the generation of intracellular ROS to produce pro-oxidant activities and cytotoxicity.

HY-N11038

Drynachromoside A	Others	Structural Classification Other Flavonoids Flavonoids Drynaria roosii Nakaike Polypodiaceae Plants Source classification
Drynachromoside A is a chromone glycoside. Drynachromoside A has biochemical effects on the osteoblastic (MC3T3-E1 cells) proliferation activities.

HY-N6729

HT-2 Toxin	Others	Terpenoids Sesquiterpenes Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Agrostidoideae Triticum aestivum L.
HT-2 Toxin is an active, deacetylated metabolite of the T-2 toxin. HT-2 toxin inhibits protein synthesis and cell proliferation in plants.

HY-125443

Lucialdehyde A	Others	Triterpenes Structural Classification Terpenoids Source classification Microorganisms
Lucialdehydes A is a lanostante-type triterpene aldehydes, isolated from the fruiting bodies of Ganoderma lucidum. Lucialdehydes A shows cytotoxic effects on tumor cells, including Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines.

HY-N3037

3-O-Acetyl-α-boswellic acid α-Boswellic acid acetate	Others	Terpenoids Other Terpenoids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants other families
3-O-Acetyl-α-boswellic acid suppresses T cell function.

HY-W008859

Tetrac Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Integrin Endogenous Metabolite	Phenols Monophenols Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Source classification Endogenous metabolite
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.

HY-125664

Lucialdehyde B	Antibiotic	Triterpenes Terpenoids Structural Classification
Lucialdehyde B is a tetracyclic triterpene isolated from the substrates of Ganoderma lucidum with antiviral and cytotoxic activities. Lucialdehyde B has cytotoxic effects against Lewis lung cancer (LLC), T-47D, Sarcoma 180 and Meth-A tumor cell lines.

HY-N7087

Tulipalin A α-Methylene butyrolactone	Drug Metabolite	Ketones, Aldehydes, Acids Source classification Plants Liliaceae Tulipa gesneriana L.
Tulipalin A (α-Methylene butyrolactone) is a glycoside. Tulipalin A is a causative allergen that induces Allergic contact dermatitides. Tulipalin A (α-Methylene butyrolactone) at low dose affects the functionality of immune cells, such as Jurkat T cells.

HY-N9737

(−)-Acutumine	Others	Pyrrole Alkaloids Structural Classification Alkaloids Menispermaceae Plants Source classification
(−)-Acutumine is a tetracyclic chloroalkaloid that exhibits selective cytotoxicity to cultured human T cells and memory-enhancing properties in the Wistar rat model.

HY-P0260

p2Ca	Others	Natural Products Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Animals
p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

HY-N4171

Dihydrocucurbitacin B	Apoptosis	Triterpenes Terpenoids Structural Classification other families Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Dihydrocucurbitacin B, a triterpene isolated from Cayaponia tayuya roots, inhibits nuclear factor of activated T cells (NFAT), induces cell cycle arrested in the G0 phase, and inhibits delayed type hypersensitivity.

HY-104026B

L-Kynurenine sulfate	Endogenous Metabolite Aryl Hydrocarbon Receptor	Classification of Application Fields Disease Research Fields Inflammation/Immunology
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype.

HY-N7915

Nepasaikosaponin K	Influenza Virus	Triterpenes Structural Classification Terpenoids Umbelliferae Bupleurum marginatum Wall. ex DC. Plants Source classification
Nepasaikosaponin K is an anti-influenza agent. Nepasaikosaponin K shows an EC₅₀ of 17.91 μM against influenza virus A/WSN/33 (H1N1) in 239T-Gluc cells.

HY-N7122

Thymopentin	Endogenous Metabolite	Phenols Monophenols Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Source classification Endogenous metabolite
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).

HY-N7122A

Thymopentin acetate	Endogenous Metabolite	Phenols Monophenols Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Endogenous metabolite
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).

HY-N7038

Phytohemagglutinin PHA-M	Others	Natural Products Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Leguminosae Glycine max (L.) merr
Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, Phaseolus vulgaris, accumulates in the parenchyma cells of the cotyledons. Phytohemagglutinin is a T-cell activator. Stimulation of human mononuclear leukocytes by Phytohemagglutinin induces the expression of ChAT mRNA, and potentiated ACh synthesis.

HY-12316

20(S)-Hydroxycholesterol 20α-Hydroxycholesterol	Smo Endogenous Metabolite	Steroids Structural Classification Endogenous metabolite Source classification Disease Research Fields Cancer Classification of Application Fields
20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells.

HY-N6734

K-252b	PKC	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
K-252b, an indolocarbazole isolated from the actinomycete Nocardiopsis, is a PKC inhibitor. K-252b can be used to inhibit extracellular kinases of cells in culture because it can’t pass through cell membrane freely .

HY-N7661

4β-Hydroxywithanolide E	PPAR	Steroids Source classification Plants Solanaceae
4β-Hydroxywithanolide E, isolated from Physalis peruviana L., inhibits adipocyte differentiation of 3T3-L1 cells through modulation of mitotic clonal expansion. 4β-Hydroxywithanolide E is an adipogenesis inhibitor and inhibits PPARγ, C/EBPα, and the adipocyte-specific molecule aP2 mRNA expression.

HY-N6681

15-Acetoxyscirpenol	Caspase Bacterial Apoptosis Antibiotic	Sesquiterpenes Terpenoids Infection Disease Research Fields Classification of Application Fields Source classification Microorganisms
15-acetoxyscirpenol, one of acetoxyscirpenol moiety mycotoxins (ASMs), strongly induces apoptosis and inhibits Jurkat T cell growth in a dose-dependent manner by activating other caspases independent of caspase-3.

HY-N7119

Cimicifugoside	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Ranunculaceae Cimicifuga foetida Linn.
Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity. Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function.

HY-N4215

11(α)-Methoxysaikosaponin F	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Umbelliferae Ajuga reptans L.
11(α)-Methoxysaikosaponin F is a triterpenoid saponin isolated from Bupleurum marginatum Wall.ex DC(ZYCH) which is a promising therapeutic for liver fibrosis. 11(α)-Methoxysaikosaponin F has an IC₅₀ of 387.7 nM with viability of hepatic stellate cells-T6 (HSCs-T6). Triterpenoid saponins have numerous targets, important network positions, and strong inhibitory activity.

HY-N10196

Cerebroside D	Endogenous Metabolite	Alkaloids Other Alkaloids Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Microorganisms
Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes.

HY-N1506

Ganodermanontriol	Others	Terpenoids Structural Classification Other Terpenoids Polyporaceae Plants Source classification Disease Research Fields Cancer Classification of Application Fields
Ganodermanontriol, a sterol isolated from Ganoderma lucidum, induces anti-inflammatory activity in tert-butyl hydroperoxide (t-BHP)-damaged hepatic cells through the expression of HO-1. Ganodermanontriol exhibits hepatoprotective activity.

HY-N1724

Concanamycin A Antibiotic X 4357B; Folimycin; X 4357B	Proton Pump Bacterial Antibiotic	Natural Products Infection Disease Research Fields Classification of Application Fields Source classification Microorganisms
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H⁺-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research^-.

HY-N0990

1,5,15-Trimethylmorindol	Others	Anthraquinones Source classification Plants Rubiaceae Morinda citrifolia Linn.
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay.

HY-N10846

Neotriptonoterpene	Others	Structural Classification Terpenoids Diterpenoids Celastraceae Tripterygium wilfordii Hook. f. Plants Source classification
Neotriptonoterpene, a compound isolated from T. regelii, shows weak cytotoxic activity against A2780, HepG2 and MCF-7 cells with IC₅₀ values of 65.80, 35.45 and 64.80 µM respectively.

HY-114495

Caerulomycin A Cerulomycin; Caerulomycin	Fungal Antibiotic	Antibiotics Structural Classification Other Antibiotics Microorganisms Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Caerulomycin A (Cerulomycin; Caerulomycin), an antifungal compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases.

HY-N0930B

Galegine hydrochloride	AMPK Bacterial	Alkaloids Other Alkaloids Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Leguminosae Galega officinalis Linn.
Galegine hydrochloride, a guanidine derivative, contributes to weight loss in mice. Guanidine hydrochloride is the compound derived from G. officinalis, which gave rise to the biguanides, metformin and phenformin. Galegine hydrochloride activates AMPK in 3T3-L1 adipocytes and L6 myotubes, as well as in the H4IIE rat hepatoma and HEK293 human kidney cell lines. Galegine hydrochloride has antibacterial activity, with minimum inhibitory concentration of 4 mg/L against Staphylococcus aureus strains.

HY-N7844

N6-Benzyladenosine Benzyladenosine	Apoptosis Adenosine Receptor	Natural Products Source classification Plants Umbelliferae Pimpinella anisum L.
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma^-.

HY-129578

Asperphenamate	Autophagy Cathepsin	Natural Products Classification of Application Fields Disease Research Fields Infection Inflammation/Immunology Source classification Microorganisms
Asperphenamate, a fungal metabolite of Aspergillus flatiipes with anti-cancer effect, exhibits IC₅₀ values of 92.3 μM, 96.5 μM and 97.9 μM in T47D, MDA-MB-231 and HL-60 cells, respectively.

HY-N0457

Chicoric acid Cichoric acid; Dicaffeoyltartaric acid	Reactive Oxygen Species Apoptosis	Phenylpropanoids Other Phenylpropanoids Phenols Polyphenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Metabolic Disease Anti-aging Source classification Plants other families
Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects.

HY-N7819

Pristane Norphytane	Others	Terpenoids Diterpenoids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants other families Marine natural products
Pristane (Norphytane) is a naturally occurring hydrocarbon oil found in small quantities in many plants, in various marine organisms, and as the most active component of mineral oil. Pristane is a non-antigenic adjuvant, and induces MHC class II-restricted, arthritogenic T cells in the rat.

HY-N6857

Armepavine	NF-κB	Isoquinoline Alkaloids Alkaloids Monophenols Phenols Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Nymphaeaceae Nelumbo nucifera Gaertn. other families
Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades.

HY-N3523

3-O-Beta-D-Glucopyranosylplatycodigenin	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants Campanulaceae Platycodon grandiflorus (Jacq.) A. DC.
3-O-Beta-D-Glucopyranosylplatycodigenin is an oleanane-type triterpenoid isolated from roots of Platycodon grandiflorum. 3-O-Beta-D-Glucopyranosylplatycodigenin exhibits anti-proliferative activities against HSC-T6 cell line with an IC₅₀ of 13.36 μM.

HY-N0704

Agrimol B	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Structural Classification Phenols Polyphenols Rosaceae Plants Agrimonia pilosa Ledeb. Metabolic Disease Disease Research Fields Classification of Application Fields
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.

HY-N0041

Ginsenoside Rb3 Gypenoside IV	NF-κB COX NO Synthase	Triterpenes Terpenoids Structural Classification Araliaceae Panax ginseng C. A. Meyer Plants Source classification Inflammation/Immunology Disease Research Fields Cancer Classification of Application Fields
Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.

HY-N6939

Pseudolaric Acid B	HBV Fungal Apoptosis Autophagy Ferroptosis	Structural Classification Terpenoids Diterpenoids Pinaceae Plants Inflammation/Immunology Infection Disease Research Fields Cancer Classification of Application Fields
Pseudolaric Acid B is a diterpene isolated from the root of Pseudolarix kaempferi (pinaceae), has anti-cancer, antifungal, and antifertile activities, and shows immunosuppressive activity on T lymphocytes. Pseudolaric Acid B inhibits hepatitis B virus (HBV) secretion through apoptosis and cell cycle arrest. Pseudolaric Acid B induces autophagy.

HY-B1021

Vincamine	Free Fatty Acid Receptor	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Plants Apocynaceae Catharanthus roseus (L.) G. Don
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation. Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research.

HY-N10648

PTP1B-IN-20	Phosphatase	Quinones Anthraquinones Plants Rubiaceae Knoxia valerianoides Thorel ex Pitard
PTP1B-IN-20 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC₅₀=1.05 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC₅₀=78.0 μM), which is a key target for type 2 diabetes inhibition.

HY-N10649

PTP1B-IN-21	Phosphatase	Quinones Anthraquinones Plants Rubiaceae Knoxia valerianoides Thorel ex Pitard
PTP1B-IN-21 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC₅₀=1.56 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC₅₀>100 μM), which is a key target for type 2 diabetes inhibition.

HY-N9965

2'-Fucosyllactose 2'-FL	TNF Receptor Interleukin Related	Saccharides Polysaccharides Inflammation/Immunology Infection Disease Research Fields Classification of Application Fields
2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines.

HY-N7634

Tectol	Farnesyl Transferase Parasite	Phenols Polyphenols Structural Classification other families Plants Source classification Infection Disease Research Fields Classification of Application Fields
Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM. Tectol is a farnesyltransferase (FTase) inhibitor with IC₅₀s of 2.09 and 1.73 μM for human and T. brucei FTase, respectively. Tectol inhibits drug-resistant strain of P. falciparum (FcB1) with an IC₅₀ of 3.44 μM.

HY-19356

Rocaglamide Roc-A	NF-κB HSP Eukaryotic Initiation Factor (eIF)	Alkaloids Other Alkaloids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Meliaceae Aglaia elliptifolia
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.

HY-116330

Hyperforin	Calcium Channel TRP Channel	Structural Classification Antibiotics Guttiferae Hyperlcurn perforatum L. Plants Source classification
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca²⁺ levels by activating Ca²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.

HY-116330A

Hyperforin dicyclohexylammonium salt Hyperforin DCHA	TRP Channel Calcium Channel	Structural Classification Natural Products Guttiferae Hyperlcurn perforatum L. Plants Source classification
Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca²⁺ levels by activating Ca²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.

Species:	Human (111) Marmoset (1) Rhesus Macaque (20) Mouse (68) Rat (24) Cynomolgus (24) Canine (5) Pig (2)
Tag:	His (152) SUMO (1) Tag Free (21) Avi (22) Myc (1) GST (3) Fc (88) Flag (3) B2M (1)
Source:	HEK293 (204) CHO (4) P. pastoris (5) Sf9 insect cells (6) E. coli (33)

Cat. No.	Product Name	Species	Source

HY-P71662

CD8 alpha Protein, Human (161a.a, HEK293, His) p32; T cell antigen Leu2; T cell co receptor; T-cell surface glycoprotein CD8 alpha chain; T-lymphocyte differentiation antigen T8/Leu-2; T8 T cell antigen; T8/Leu-2 T-lymphocyte differentiation antigen	Human	HEK293

HY-P70497

CD7 Protein, Human (HEK293, His)
T-cell Antigen CD7; GP40; T-cell Leukemia Antigen; T-cell Surface Antigen Leu-9; TP41; CD7
Human HEK293
HY-P72361

CD7 Protein, Human (Biotinylated, HEK293, His-Avi)
T-cell Antigen CD7; GP40; T-cell Leukemia Antigen; T-cell Surface Antigen Leu-9; TP41
Human HEK293
HY-P75654

CD3D Protein, Mouse (HEK293, Fc)
T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; T3d
Mouse HEK293
HY-P72900

CD4 Protein, Ferret (HEK293, His)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Others HEK293
HY-P72902

CD4 Protein, Human (HEK293, Fc)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Human HEK293
HY-P72904

CD4 Protein, Mouse (HEK293, His)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Mouse HEK293
HY-P72905

CD4 Protein, Rat (HEK293, His)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Rat HEK293
HY-P72903

CD4 Protein, Human (HEK293, His-Fc)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Human HEK293
HY-P72906

CD4 Protein, Rhesus Macaque (HEK293, His)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Rhesus Macaque HEK293
HY-P74300

CD4 Protein, Rhesus Macaque (HEK293, Fc)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Rhesus Macaque HEK293
HY-P77517

CD4 Protein, Mouse (Biotinylated, HEK293, His)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Mouse HEK293
HY-P70537

CD4 Protein, Human (365a.a, HEK293, His)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; sCD4
Human HEK293
HY-P72901

CD4 Protein, Human (208a.a, HEK293, His)
T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3; CD4
Human HEK293
HY-P76803

CD3D Protein, Canine (HEK293, Fc)
T-cell Surface Glycoprotein CD3 Delta Chain; T-cell Receptor T3 Delta Chain; CD3d; CD3D; T3D
Canine HEK293

HY-P7808

CD7 Protein, Cynomolgus (HEK293, His) rCynIg-like domain-containing protein/CD7, His; T-cell Antigen CD7; GP40; T-cell Leukemia Antigen; T-cell Surface Antigen Leu-9; TP41; CD7	Cynomolgus	HEK293

HY-P72728

CD3 delta Protein, Cynomolgus (HEK293, His)
T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D
Cynomolgus HEK293
HY-P70506

CD3 epsilon Protein, Human (HEK293, His)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Human HEK293
HY-P76788

CD3 epsilon Protein, Rat (HEK293, Fc)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Rat HEK293
HY-P77320

CD3 epsilon Protein, Canine (HEK293, Fc)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Canine HEK293

HY-P7879

CD3D Protein, Human (HEK293, His) rHuT-cell surface glycoprotein CD3 delta chain/CD3D, His; T-cell Surface Glycoprotein CD3 Delta Chain; T-cell Receptor T3 Delta Chain; CD3d; CD3D; T3D	Human	HEK293

HY-P76789

CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Rhesus Macaque HEK293
HY-P76791

CD3 epsilon Protein, Rhesus Macaque (HEK293, His)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Rhesus Macaque HEK293
HY-P76790

CD3 epsilon Protein, Rhesus Macaque (HEK293, His-Fc)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Rhesus Macaque HEK293

HY-P7882

CD2 Protein, Human (HEK293, His) rHuT-cell surface antigen CD2/LFA-3 receptor, His; T-cell surface antigen CD2; Erythrocyte receptor; LFA-2; LFA-3 receptor; Rosette receptor; T-cell surface antigen T11/Leu-5	Human	HEK293
CD2 Protein, Human (HEK 293, His) is a transmembrane cell surface glycoprotein found on virtually all T cells, thymocytes, and NK cells. CD2 ligation by CD58 has been shown to mediate T cell adhesion, T cell activation, T cell cytokine production and T cell and NK cells cytotoxic activity.

HY-P70091

CD3 delta Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 delta chain/CD3d, Fc ; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD3d; CD3D	Cynomolgus	HEK293

HY-P70682

CD3 epsilon Protein, Human (104a.a, HEK293, Fc)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Human HEK293
HY-P70824

CD3 epsilon Protein, Human (27a.a, HEK293, Fc)
T-cell Surface Glycoprotein CD3 Epsilon Chain; T-cell Surface Antigen T3/Leu-4 Epsilon Chain; CD3e; CD3E; T3E
Human HEK293
HY-P73189

IL-2 Protein, Rat
Interleukin-2; T-cell growth factor; TCGF
Rat E. coli

HY-P70976

TIM-4/TIMD-4 Protein, Human (HEK293, His) T-cell immunoglobulin and mucin domain-containing protein 4; TIMD-4; T-cell immunoglobulin mucin receptor 4; TIM-4; T-cell membrane protein 4; TIMD4; TIM4	Human	HEK293

HY-P70646

IL-2 Protein, Mouse (149a.a)
aldesleukin; interleukin 2; interleukin-2; IL-2; IL2; T-cell growth facter; T cell growth factor; TCGF
Mouse E. coli
HY-P71379

TRAT1 Protein, Human (His)
T-cell Receptor-Associated Transmembrane Adapter 1; T-cell Receptor-Interacting Molecule; TRIM; pp29/30; TRAT1; TCRIM; HSPC062
Human E. coli
HY-P72922

CD6 Protein, Human (HEK293, Fc)
T-cell differentiation antigen CD6; T12; TP120; CD6
Human HEK293
HY-P72923

CD6 Protein, Mouse (HEK293, Fc)
T-cell differentiation antigen CD6; T12; TP120; CD6
Mouse HEK293
HY-P72924

CD6 Protein, Rat (HEK293, His)
T-cell differentiation antigen CD6; T12; TP120; CD6
Rat HEK293
HY-P74301

CD3D-CD3E Heterodimer Protein, Human (HEK293)
T-cell receptor T3 delta chain; CD3D; T3D; CD3E; T3E
Human HEK293
HY-P71845

CD3 gamma Protein, Cynomolgus (P.pastoris, His)
CD3GT-cell surface glycoprotein CD3 gamma chain; T-cell receptor T3 gamma chain; CD antigen CD3g
Cynomolgus P. pastoris
HY-P72271

TRAC Protein, Human (P.pastoris, His)
TRAC; TCRA; T cell receptor alpha constant
Human P. pastoris
HY-P7037

IL-2 Protein, Human
rHuIL-2; IL2; T-cell Growth Factor; TCGF; Aldesleukin
Human E. coli

IL-2 Protein, Human is an adjunctive immunotherapeutic agent to treat tuberculosis (TB).

HY-P7077

IL-2 Protein, Mouse rMuIL-2; IL2; T-cell Growth Factor; TCGF; Aldesleukin	Mouse	E. coli
IL-2 Protein, Mouse is an immunomodulatory cytokine with widely varying functions including promotion of apoptosis, proliferation and survival of lymphocytes.

HY-P73188

IL-2 Protein, Canine (C147S)
Interleukin-2; T-cell growth factor; TCGF
Canine E. coli
HY-P73501

CD6 Protein, Mouse (396a.a, HEK293, His)
T-cell differentiation antigen CD6; T12; TP120; CD6
Mouse HEK293
HY-P75427

CD27/TNFRSF7 Protein, Rat (HEK293, Fc)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Rat HEK293
HY-P75632

CD27/TNFRSF7 Protein, Human (sf9, His)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Human Sf9 insect cells
HY-P75634

CD27/TNFRSF7 Protein, Human (HEK293, Fc)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Human HEK293
HY-P76216

CD27/TNFRSF7 Protein, Mouse (HEK293, His)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Mouse HEK293
HY-P72698

CD96 Protein, Human (482a.a, HEK293, His)
T-cell surface protein tactile; cell surface antigen CD96; CD96
Human HEK293
HY-P72699

CD96 Protein, Mouse (515a.a, HEK293, His)
T-cell surface protein tactile; cell surface antigen CD96; CD96
Mouse HEK293
HY-P75372

CD96 Protein, Human (503a.a, HEK293, His)
T-cell surface protein tactile; cell surface antigen CD96; CD96
Human HEK293
HY-P75662

CD96 Protein, Mouse (536a.a, HEK293, His)
T-cell surface protein tactile; cell surface antigen CD96; CD96
Mouse HEK293
HY-P78660

CD96 Protein, Human (C110S, HEK293, His)
T-cell surface protein tactile; cell surface antigen CD96; CD96
Human HEK293

HY-P70550

CD137/4-1BB Protein, Cynomolgus (HEK293, His) CD137; ILA; TNFRSF9; 4-1BB ligand receptor; CDw137; T-cell antigen 4-1BB homolog; T-cell antigen ILA	Cynomolgus	HEK293
4-1BB (CD137; TNFRSF9), is a surface glycoprotein, a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. CD137/4-1BB Protein, Cynomolgus (HEK293, His) has 163 amino acids (L24-Q186), produced by HEK293 cells with C-terminal 6*His-tag.

HY-P71723

CD3 epsilon Protein, Mouse (P.pastoris, His)
Cd3eT-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD antigen CD3e
Mouse P. pastoris

HY-P70826

TIM-3/HAVCR2 Protein, Mouse (172a.a, HEK293, Fc) Hepatitis A virus cellular receptor 2 homolog; HAVcr-2; T-cell immunoglobulin and mucin domain-containing protein 3; T-cell immunoglobulin mucin receptor 3; T-cell membrane protein 3; Tim3; Timd3	Mouse	HEK293

HY-P75633

CD27/TNFRSF7 Protein, Human (Biotinylated, sf9, His)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Human Sf9 insect cells
HY-P75371

CD96 Protein, Human (Biotinylated, 503a.a, HEK293, His)
T-cell surface protein tactile; cell surface antigen CD96; CD96
Human HEK293
HY-P75626

CD22 Protein, Rhesus Macaque (HEK293, Fc)
B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14
Rhesus Macaque HEK293
HY-P75627

CD22 Protein, Rhesus Macaque (HEK293, His)
B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14
Rhesus Macaque HEK293

HY-P7037A

IL-2 Protein, Human (CHO) rHuIL-2; IL2; T-cell Growth Factor; TCGF; Aldesleukin	Human	CHO
IL-2 Protein, Human (CHO) is a CHO cell derived adjunctive immunotherapeutic agent to treat tuberculosis (TB).

HY-P75630

CD27/TNFRSF7 Protein, Human (Biotinylated, HEK293, Fc-Avi)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Human HEK293
HY-P700131AF

Animal-Free IL-5 Protein, Human (His)
Interleukin-5; B-cell differentiation factor I; EosinophIL differentiation factor; T-cell replacing factor; TRF; IL5
Human E. coli

HY-P70678

4-1BB/TNFRSF9 Protein, Human (163a.a, HEK293, His) CD137; ILA; TNFRSF9; 4-1BB ligand receptor; CDw137; T-cell antigen 4-1BB homolog; T-cell antigen ILA	Human	HEK293
4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Human 4-1BB protein is a surface glycoprotein with a transmembrane domain (187-213 a.a.). 4-1BB/TNFRSF9 Protein, Human (163a.a, HEK293, His) is the extracellular part (L24-Q186) of 4-1BB protein, produced by HEK293 cells with C-terminal 6*His-tag.

HY-P70681

4-1BB/TNFRSF9 Protein, Human (163a.a, HEK293, Fc) CD137; ILA; TNFRSF9; 4-1BB ligand receptor; CDw137; T-cell antigen 4-1BB homolog; T-cell antigen ILA	Human	HEK293
4-1BB/TNFRSF9 Protein, Human (HEK 293, Fc), a recombinant human 4-1BB/TNFRSF9 Protein produced in HEK293 cells, has an Fc fragment at the C-terminus. Recombinant Human 4-1BBRTNFRSF9, an inducible T cell molecule belonging to the TNF receptor superfamily, could promote the expansion of antigen-specific T cells and prevent activation-induced death of CD8⁺ T cells.

HY-P7083

IL-9 Protein, Mouse (CHO) rMuIL-9; Cytokine P40; T-cell Growth Factor P40	Mouse	CHO
IL-9 Protein, Mouse (CHO), derived from CHO cell, is a member of the TH2 cytokine family. IL-9 Protein, Mouse (CHO) has recently been implicated as an essential factor in determining mucosal immunity and susceptibility to atopic asthma.

HY-P7046

IL-9 Protein, Human (CHO) rHuIL-9; Cytokine P40; T-cell Growth Factor P40	Human	CHO
IL-9 Protein, Human (CHO) is a CHO cell derived immunoregulatory cytokine produced by IL-2 activated Th2 lymphocytes.

HY-P74273

CD7 Protein, Rat (HEK293, Fc)
CD7; LEU-9; T-cell antigen CD7
Rat HEK293
HY-P78312

IL-2 Protein, Mouse (HEK293, His-Avi)
IL2; T-cell growth factor; TCGF; Aldesleukin
Mouse HEK293
HY-P76215

CD27/TNFRSF7 Protein, Mouse (182a.a, HEK293, Fc)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Mouse HEK293

HY-P70090

CD3 epsilon Protein, Cynomolgus (HEK293, Fc) rCynT-cell surface glycoprotein CD3 epsilon chain/CD3E, Fc ; CD3 epsilon; CD3e antigen; CD3e antigen, epsilon polypeptide (TiT3 complex); CD3e molecule, epsilon (CD3-TCR complex); CD3e; CD3-epsilon; FLJ18683; T3E; T-cell antigen receptor complex, epsilon subunit of T3; T-cell surface antigen T3/Leu-4 epsilon chain	Cynomolgus	HEK293

HY-P75426

CD27/TNFRSF7 Protein, Rhesus Macaque (192a.a, HEK293, Fc)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Rhesus Macaque HEK293
HY-P75631

CD27/TNFRSF7 Protein, Human (192a.a, HEK293, His-Fc)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Human HEK293
HY-P76217

CD27/TNFRSF7 Protein, Mouse (182a.a, HEK293, His-Fc)
CD27 antigen; T cell activation antigen CD27; T14; TNFRSF7
Mouse HEK293
HY-P76220

CD3 zeta/CD247 Protein, Human (GST)
T-cell surface glycoprotein CD3 zeta chain; CD247; CD3Z; T3Z; TCRZ
Human E. coli
HY-P70612

IL-5 Protein, Human (HEK293, His)
Interleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5
Human HEK293
HY-P70746

IL-5 Protein, Mouse (HEK293, His)
Interleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5
Mouse HEK293
HY-P72387

IL-5 Protein, Human (Biotinylated, HEK293, His-Avi)
Interleukin-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5
Human HEK293
HY-P700215AF

Animal-Free IL-5 Protein, Mouse (His)
Interleukin-5; IL-5; B-cell differentiation factor I; EosinophIL differentiation factor; T-cell replacing factor; TRF; IL5
Mouse E. coli
HY-P70775

IL-2 Protein, Human (C145S)
Interleukin-2; IL-2; T-cell growth factor; TCGF; Aldesleukin
Human E. coli
HY-P74313

CD28 Protein, Human (HEK293)
CD28; T-cell-specific surface glycoprotein CD28; Tp44
Human HEK293
HY-P78151

IL-2 Protein, Mouse (Biotinylated, HEK293, His-Avi)
IL2; T-cell growth factor; TCGF; Aldesleukin
Mouse HEK293
HY-P78551

GMP IL-2 Protein, Human
Interleukin-2; IL-2; T-cell Growth Factor; TCGF; Aldesleukin; IL2
Human E. coli
HY-P7037B

IL-2 Protein, Human (His)
Interleukin-2; IL-2; T-cell Growth Factor; TCGF; Aldesleukin; IL2
Human E. coli
HY-P70646AF

Animal-Free IL-2 Protein, Mouse (His)
rMuIL-2; IL2; T-cell Growth Factor; TCGF; Aldesleukin
Mouse E. coli

HY-P71995

TIM-3/HAVCR2 Protein, Mouse (HEK 293, hFc) Havcr2; Tim3; Timd3; Hepatitis A virus cellular receptor 2 homolog; HAVcr-2; T-cell immunoglobulin and mucin domain-containing protein 3; TIMD-3; T-cell immunoglobulin mucin receptor 3; TIM-3; T-cell membrane protein 3; CD antigen CD366	Mouse	HEK293

HY-P7810

CD137/4-1BB Protein, Cynomolgus (HEK293, Fc)
rCynCD137/4-1BB, Fc; CD137; ILA; TNFRSF9; 4-1BB ligand receptor; CDw137; T-cell antigen 4-1BB homolog; T-cell antigen ILA
Cynomolgus HEK293
HY-P75430

Siglec-2/CD22 Protein, Rat (692a.a, HEK293, His)
B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14
Rat HEK293
HY-P75431

Siglec-2/CD22 Protein, Rat (692a.a, HEK293, Fc)
B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14
Rat HEK293

HY-P72351

Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His-Avi) B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigenMGC130020; CD22; T-cell surface antigen Leu-14	Human	HEK293

HY-P70460

IL-13 Protein, Mouse Interleukin-13; IL-13; T-cell Activation Protein P600; Il13; Il-13	Mouse	E. coli
IL-13 Protein, Mouse is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and NK cells. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-8.

HY-P71009

TIGIT Protein, Mouse (118a.a, HEK293, Fc)
T-cell immunoreceptor with Ig and ITIM domains; Tigit
Mouse HEK293
HY-P74309

CD28 Protein, Rat (HEK293, His)
CD28; T-cell-specific surface glycoprotein CD28; Tp44
Rat HEK293
HY-P74310

CD28 Protein, Rat (HEK293, Fc)
CD28; T-cell-specific surface glycoprotein CD28; Tp44
Rat HEK293
HY-P74312

CD28 Protein, Human (HEK293, Fc)
CD28; T-cell-specific surface glycoprotein CD28; Tp44
Human HEK293
HY-P74324

CD2 Protein, Canine (HEK293, His)
T-cell surface antigen CD2; LFA-2; CD2; SRBC
Canine HEK293
HY-P74325

CD2 Protein, Canine (HEK293, Fc)
T-cell surface antigen CD2; LFA-2; CD2; SRBC
Canine HEK293
HY-P75425

CD28 Protein, Cynomolgus (HEK293, Fc)
CD28; T-cell-specific surface glycoprotein CD28; Tp44
Cynomolgus HEK293
HY-P75434

CD2 Protein, Cynomolgus (HEK293, His)
T-cell surface antigen CD2; LFA-2; CD2; SRBC
Cynomolgus HEK293
HY-P75435

CD2 Protein, Cynomolgus (HEK293, hFc)
T-cell surface antigen CD2; LFA-2; CD2; SRBC
Cynomolgus HEK293
HY-P78314

IL-5 Protein, Mouse (HEK293, His-Avi)
Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF
Mouse HEK293
HY-P78467

IL-5 Protein, Human (HEK293, His-Avi)
Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF
Human HEK293
HY-P700218AF

Animal-Free IL-9 Protein, Mouse (His)
rMuIL-9; Cytokine P40; T-cell Growth Factor P40
Mouse E. coli
HY-P72742

CD27/TNFRSF7 Protein, Human (172a.a, HEK293, His-Fc)
CD27 antigen; CD27; T-cell activation antigen CD27; T14; TNFRSF7
Human HEK293
HY-P72743

CD27/TNFRSF7 Protein, Mouse (159a.a, HEK293, His-Fc)
CD27 antigen; CD27; T-<

T cell

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products